

CURRICULUM VITAE

Nelson Barnett Watts, MD, FACP, FACE

CURRENT TITLES AND AFFILIATIONS:

Professor of Medicine, University of Cincinnati College of Medicine
Director, University of Cincinnati Bone Health and Osteoporosis Center

DATE, PLACE OF BIRTH:

_____ 25

MARITAL STATUS:

HOME ADDRESS:

OFFICE ADDRESS:

Bone Health and Osteoporosis Center
University of Cincinnati Medical Center
222 Piedmont Avenue, Suite 4300
Cincinnati OH 45219

LICENSED: Georgia _____ North Carolina _____ Ohio _____ DEA Certificate _____

CERTIFIED:

American Board of Internal Medicine
ABIM Subspecialty, Endocrinology and Metabolism
American Board of Bioanalysis, Laboratory Director
International Society for Clinical Densitometry (1996)

EDUCATION:

1966, BS University of North Carolina, Chapel Hill
1969, MD University of North Carolina School of Medicine, Chapel Hill

POST GRADUATE TRAINING:

1969-1970 Intern in Medicine, Eugene Talmadge Memorial Hospital, Augusta, Georgia
1970-1971 Fellow in Endocrinology, North Carolina Memorial Hospital, Chapel Hill
1971-1971 Resident in Medicine, Charlotte (NC) Memorial Hospital

HOSPITAL AFFILIATIONS:

University Hospital, Cincinnati OH

PROFESSIONAL SOCIETIES:

American Association of Clinical Endocrinologists
 American College of Physicians
 American Society for Bone and Mineral Research
 International Bone and Mineral Society
 International Osteoporosis Foundation

International Society for Calcium Related Hormones
 International Society for Clinical Densitometry
 National Osteoporosis Foundation (USA)
 The Endocrine Society
 The North American Menopause Society

EDITORIAL BOARDS:

Editor, *The Emory Clinic Dialogue*, 1988-1996

Associate Editor, *Endocrine Practice*, 1998-2001

Editorial Boards: *Diabetes Care*, 1992-1994

Endocrine Practice, 1996-1998

Journal of Clinical Densitometry, 1997-

Clinical Journal of Women's Health, 2000-

Guest Editor, *The American Journal of the Medical Sciences* (December, 1996 and January, 1997)

Guest Editor, *Endocrinology and Metabolism Clinics of North America* (June, 1998)

Ad-hoc Reviewer:

American Family Physician

American Journal of Medicine

American Journal of the Medical Sciences

Archives of Pathology and Laboratory Medicine
Bone

British Medical Journal

Calcified Tissue International

Canadian Medical Association Journal

Clinical Chemistry

Drugs and Aging

Endocrine Practice

Journal of the American Geriatric Society

Journal of the American Medical Association

Journal of Bone and Mineral Research *Journal of*
Clinical Densitometry

Journal of Clinical Endocrinology and Metabolism

Journal of Family Practice

Journal of Pediatric Endocrinology and Metabolism

Journal of Rheumatology

Journal of Women's Health

Mayo Clinic Proceedings

Osteoporosis International

Quarterly Journal of Medicine

Seminars in Arthritis and Rheumatism

Southern Medical Journal

The Neurologist

PREVIOUS FACULTY APPOINTMENTS:

University of North Carolina School of Medicine

1976-1981 Clinical Assistant Professor of Medicine

1981-1983 Clinical Associate Professor of Medicine

Emory University School of Medicine

1983-1984 Senior Associate in Medicine

1984-1988 Assistant Professor of Medicine

1988-1996 Associate Professor of Medicine

1996-2001 Professor of Medicine

University of Cincinnati College of Medicine

2001- Professor of Medicine

PREVIOUS PRACTICE AND HOSPITAL APPOINTMENTS:

1972-1983 Private practice, endocrinology, Asheville, NC

Attending Physician, Memorial Mission Hospital and St. Joseph's Hospital (Asheville, NC)

1983-2001 Attending Physician, Emory University Hospital, Grady Memorial Hospital (Atlanta, GA)

Endocrinologist, The Emory Clinic, Inc.

1990-2001 Director, Osteoporosis and Bone Health Program, The Emory Clinic

SELECTED AWARDS AND RECOGNITION:

American College of Physicians, Fellow, 1977-
 American Society of Clinical Pathologists, Continuing Education Council Commissioner's Medal, 1989
 American Society of Clinical Pathologists President's Award, 1990
 American College of Endocrinology, Fellow, 1994-
 President, Buncombe County (NC) Medical Society, 1980
 President, American Diabetes Association Georgia Affiliate, 1990-1991
 President, International Society for Clinical Densitometry, 2001-
 American Association of Clinical Endocrinologists, Board of Directors 1994-
 National Osteoporosis Foundation Scientific Advisory Committee, 1999-
 International Osteoporosis Foundation Committee of Scientific Advisors, 1999-
 Principal Investigator, Women's Health Initiative Atlanta Vanguard Clinical Center, 1999-2001
 Listed in Castle-Connolly's *America's Top Doctors*, 2001-
 President, American College of Endocrinology, 2002-

OTHER AWARDS AND RECOGNITION:

1980 Certificate of Appreciation, Mountain Area Health Education Center, Family Practice Residents
 1983 Award for Significant Contributions to the Health Professionals of Western North Carolina
 1989-1995 The Emory Clinic Board of Directors Administrative Committee/Executive Committee
 1993 Co-Director, AACE/American Thyroid Association Thyroid Workshop, Atlanta, October 9
 1994 Journal of the American Medical Association, "Endocrinology" for yearly Contempo issue
 1996 Nominee, "Best Attending, Medicine," Emory University School of Medicine Class of '96
 1996 Co-Director, AACE Clinical Symposium on Osteoporosis, Columbia, SC, March 23-24
 1996 Journal of the American Medical Association, "Endocrinology" for yearly Contempo issue
 1997 Co-Director, EUSM CME course, "Osteoporosis and Bone Densitometry," May 3 and December 13
 1998 Director, AACE Clinical Symposium on Osteoporosis, Marina del Rey, CA, January 9 and 10
 1998 Program Co-chairman, ISCD Fourth Annual Meeting, Orlando, January 15-18
 1998 Director, AACE Clinical Symposium on Osteoporosis, San Antonio, TX, February 20 and 21
 1998 Co-Director, EUSM CME course, "Osteoporosis and Bone Densitometry," May 23
 1998 Best Speaker, 16th Annual Rheumatology on the Beach, Sandestin, FL
 1999 American Association of Clinical Chemistry, 22nd Annual Beckman Conference Lecturer
 1999 American Association of Clinical Chemistry Annual Meeting, Best Speaker
 2000- American Association of Clinical Endocrinologists, Chair, Osteoporosis Awareness Initiative
 2000-2001 AACE, Co-Chair, Osteoporosis Guidelines Revision Committee

Grant Reviewer, National Osteoporosis Foundation, National Institutes of Health (NIDDK)

National Committee for Clinical Laboratory Standards

Subcommittee on Urinalysis, 1989-1996

Subcommittee on Hemoglobinopathies (glycohemoglobins), 1990-1998

American Board of Internal Medicine, Questioner for Recertification Examination, 1993-1999

Accreditation Council for Graduate Medical Education, Pre-Reviewer for Endocrinology Training Programs, 1994-1999

Listed in The Best Doctors in America: Southeast Region, 1996-1997

Invited participant, University of Virginia International Workshop on Breast Cancer: Treatment of Estrogen Deficiency
 Symptoms in Women Surviving Breast Cancer, September 21-23, 1997

Listed in The Best Doctors in America, 1998-

Women's Health Initiative, Calcium/Vitamin D Committee, 1999-

AMA Osteoporosis CME Advisory Board, 1999-

AMA Women's Health Information Center, Reviewer, 1999-

RESEARCH AWARDS:

Principal Investigator, ongoing trials:

- Randomized, double-blind, placebo-controlled, multi-dose phase 2 study to determine the efficacy, safety and tolerability of AMG 162 in the treatment of postmenopausal women with low bone mineral density. Amgen, 06/2002-05/2005
- Multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of zoledronic acid in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D. Novartis Pharmaceuticals, 06/2002-08/2006
- Phase III, multinational, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of transdermal testosterone (300 µg/day) for 24 weeks and safety for a further 28-week open-label period in women with hypoactive sexual desire disorder on concurrent estrogen replacement therapy who have undergone hysterectomy and bilateral oophorectomy. Procter & Gamble Pharmaceuticals, 06/2002-05/2004
- Randomized, double-blind, placebo-controlled, parallel group, multicenter, two-year Phase III study to determine the efficacy of risedronate therapy administered 35 mg once a week in men with osteoporosis. Aventis Pharmaceuticals, 07/2002-07/2004.

Principal Investigator, completed trials (selected):

- Intermittent cyclical etidronate, with and without phosphate, double-blind placebo-controlled trial in postmenopausal osteoporosis. Norwich Eaton Pharmaceuticals, 5/86-2/90, extended 2/90-2/94
- Estrogen compared with estrogen plus androgen, double-blind trial after oophorectomy. Reid Rowell, 12/87-6/88
- Alendronate, double-blind phase III trial for osteoporosis. Merck, 1/91-11/95, extended 11/95-6/2001
- Nasal spray calcitonin placebo-controlled trial for osteoporosis (PROOF). Sandoz Pharmaceuticals, 2/91-12/96; extended 12/96-12/98
- Esterified estrogen dose-ranging study, double-blind, placebo-controlled trial. Solvay Pharmaceuticals, 12/92-6/95
- Risedronate phase III placebo-controlled study in the treatment of postmenopausal osteoporosis. Procter & Gamble Pharmaceuticals, 11/93-11/98, extended 11/96-6/99
- Raloxifene, a long-term comparison with placebo and conjugated estrogen in the prevention of osteoporosis. Eli Lilly and Company, 11/93-11/99
- Raloxifene, comparison of raloxifene and placebo in the treatment of postmenopausal women with osteoporosis (MORE). Eli Lilly and Company (MORE), 10/94-10/99
- Ibandronate by intermittent IV injection, double-blind placebo-controlled study in patients with postmenopausal osteoporosis. Boehringer Mannheim (Roche), 10/95-10/99
- Estradiol matrix transdermal therapeutic system (Vivelle), a randomized, double-blind, placebo-controlled trial in the prevention of postmenopausal bone loss. Ciba-Geigy, 11/1/95-11/19/99
- Ibandronate (ME 4380) oral dosing, double-blind placebo-controlled, randomized in patients with postmenopausal osteoporosis. Boehringer Mannheim (Roche), 1/97-7/2000
- Estrogen transdermal system, a double-blind, placebo-controlled, dose-ranging study in hysterectomized postmenopausal women. Procter & Gamble Pharmaceuticals, 1/96-7/99
- Risedronate, double-blind trial to evaluate modified dosing instructions for 5 mg oral risedronate in postmenopausal osteopenic and osteoporotic women. Procter & Gamble Pharmaceuticals, 7/98-7/99
- Evaluation of a peripheral bone assessment technology: development of a normative database with an African-American female population. Schick Technologies, 7/98-7/99
- Alendronate 70 mg once weekly vs. 35 mg twice weekly vs 10 mg daily in postmenopausal women. Merck, 12/97-12/2000
- Alendronate 35 mg once weekly vs. 5 mg daily in recently postmenopausal women. Merck, 3/98-3/2001
- IMPACT, a multicenter study to assess the impact of physician's reinforcement on the subject's compliance and persistence on treatment using feedback on bone markers in previously undiagnosed postmenopausal osteoporotic women treated with risedronate. Aventis Pharmaceuticals, 10/99-4/2001

Principal Investigator, completed trials (selected):

- Female testosterone patch study, phase II, multiple -site, randomized, double-blind, placebo-controlled study to evaluate the efficacy of three transdermal testosterone doses in women with low libido who have undergone hysterectomy and bilateral oophorectomy. Procter & Gamble Pharmaceuticals, 3/99-9/2002
- Risedronate weekly 50 mg or 35 mg vs. daily 5 mg in postmenopausal women. Aventis Pharmaceuticals, 9/99-3/2002
- PTH, double-blind, placebo-controlled, phase III trial of the effect of recombinant human parathyroid hormone 1-84 (ALX1-11) on fracture incidence in women with postmenopausal osteoporosis. NPS Allelix Pharmaceuticals 7/2000-9/2003.

**APPEARS THIS WAY
ON ORIGINAL**

CURRENT STAFF AND COMMITTEE POSITIONS:

American Association of Clinical Endocrinologists

Board of Directors, 1995-

Continuing Medical Education Committee 1996-

Medical Student & Resident Subcommittee of the Membership Committee, 2002-

Public Initiatives Subcommittee 2002-

Awards Committee 2002-

Electronic Medical Record Task Force 2002-

American College of Endocrinology

Board of Trustees, 1999-

President 2002-

American Society for Bone and Mineral Research

National Meeting Program Committee, 1996-

Member, Professional Practice Committee, 1998-

Chair, Professional Practice Committee, 2000-

International Osteoporosis Foundation

Committee of Scientific Advisors, 2000-

International Society for Clinical Densitometry

Editorial Board, *Journal of Clinical Densitometry*, 1997-

• President, 2001-

National Osteoporosis Foundation

Committee on BMD Simplification, 1998-

Scientific Advisory Committee, 1999-

Committee to Revise Guidelines, 2000-

University of North Carolina Medical Alumni Association

Loyalty Fund Steering Committee, 1994-

**APPEARS THIS WAY
ON ORIGINAL**

PAST STAFF AND COMMITTEE POSITIONS, NATIONAL ORGANIZATIONS:

American Association of Clinical Endocrinologists

Endocrine Practice Editorial Board 1996-1998, Associate Editor 1998-2001
Chair, ad-hoc Administrative Committee, 1996
Osteoporosis Task Force, 1996
Oversight and Ethical Affairs Committee, 1997-2002
Nominating Committee, 1997, 1999, 2000
Annual Meeting Program Committee, 1995-1998
Chair, Clinical Symposia/Mini-Fellowships Committee, 1996-1998
Continuing Medical Education Committee, 1996-1998, Chair 1998-2000
Strategic Planning Committee, 1997-1999
Awards Committee, 1999-2000
Chair, Osteoporosis Awareness Initiative, 1999-2001
Co-Chair, Osteoporosis Guidelines Revision, 2000-2001

American College of Endocrinology

Chair, ad-hoc Committee on Selection of Officers, 2000
Member, Endocrine Fellows-in-Training Committee, 2000
Vice-President, 2001-2002
Nominating Committee, 2002

American Diabetes Association

ADA North Carolina Affiliate:

NC Patient Education Committee, 1976, 1977
Blue Ridge Chapter Board of Directors, 1977-1981

ADA Georgia Affiliate:

Chairman, Professional Education Committee, 1988-1990, Co-chair 1993-1994
President Elect, 1990-1991; President, 1991-1992; Past President, 1992-1993
Board of Directors, 1989-1993; Executive Committee, 1990-1993

ADA Southeast Region:

Annual Regional Scientific Conference, Program Committee 1988-1993, Chairman 1991, 1992

ADA National:

Clinical Education Program (CEP) Faculty, 1985, 1989-1990, 1992-1993
Council on Complications, 1988-1998
Council on Education, 1988-1998
Delegate to Central Council, 1990-1992, Delegation Chair, 1991
National Meeting Abstract Reviewer, 1993
Editorial Board, *Diabetes Care*, 1992-1994

American Society for Bone and Mineral Research

National Meeting Abstract Reviewer, 1996-
Co-Chair, 1997 Annual Meeting Session "Osteoporosis Treatment"
National Meeting Program Committee, Chair, Assessment of Disorders of Bone and Mineral Category 2001-
Organizing Committee, "Osteoporosis Trials: Ethical Considerations in Study Design," 2002

PAST STAFF AND COMMITTEE POSITIONS, NATIONAL ORGANIZATIONS:

American Society of Clinical Pathologists

Member, Council on Clinical Chemistry, 1984-1990

Member, Editorial Committee, Project 180, 1985

Member, Committee on Physicians Office Laboratories, 1986-1987

Centers for Disease Control and Prevention

Planning and Publications Committees, INSTITUTE '89, 1987-1989

Advisory Panel, CLIA '88, 1991

Working Group on Preanalytical Criteria for Measurement of Pyridinoline and Deoxypyridinoline, 1998-2001

International Society for Clinical Densitometry (ISCD)

Co-chair, Annual Meeting Program Committee, 1998

Scientific Advisory Board, 1998-1999

Chairman, Education Committee, 1999-2000

President-elect 1999-2001

National Osteoporosis Foundation

Task Force on Clinical Use of Bone Markers, 1997-2000

Leadership Committee, Atlanta "America Walks for Strong Women," 1997

University of North Carolina Medical Alumni Association

Western District Representative, 1983

* Delegate-at-large, 1985-1989

Visiting Committee, 1986-1992

Secretary, 1989-1992

**APPEARS THIS WAY
ON ORIGINAL**

PAST STAFF AND COMMITTEE POSITIONS, NORTH CAROLINA, 1972-1983 (SELECTED):

Buncombe County (North Carolina) Medical Society

- President-elect, 1979; President, 1980
- Board of Directors, 1975, 1977, 1979-1983
- Member, Education Committee, 1977
- Delegate to the NC Medical Society, 1977, 1979-1983

Memorial Mission Hospital (Asheville, North Carolina)

- Medical Education Committee (member 1973-1976, chairman 1977)
- Bylaws Committee (member 1975, 1976, chairman 1977)
- Member, Medical Administrative Committee, 1976-1978
- Chairman, Committee on Joint Hospital Services, 1977
- Secretary-Treasurer of the Medical Staff, 1976, 1977
- Chairman, Department of Internal Medicine, 1978

Mountain Area Health Education Foundation (Asheville, North Carolina)

- Board of Directors, 1981-1983
- Chairman, Search Committee for Executive Director, 1982

North Carolina Medical Society

- Member, Committee on Social Services, 1980-1982
- Member, Committee on Communications, 1980-1982

Saint Joseph's Hospital (Asheville, North Carolina)

- Vice-Chairman, Department of Medicine, 1974
- Chairman, Department of Internal Medicine, 1975
- Bylaws Committee (member 1975, 1976, chairman 1977)
- Executive Committee, 1975
- * Chairman, Medical Education Committee, 1976

PAST STAFF AND COMMITTEE POSITIONS, GEORGIA, 1983-2001 (SELECTED)

Emory University Hospital

- Diabetes Task Force, 1983-1987
- Patient Education Committee, 1983-1988
- Pharmacy and Therapeutics Committee, 1984-1990
- Quality Assurance Coordinator (Endocrinology), 1987-1995
- Medical Quality Assurance Committee, 1988-1995
- Laboratory Advisory Committee, 1988-1989
- Chief of Teaching Programs and Clinical Activities for Endocrinology and Metabolism, 1990-1998
- Quality Improvement Steering Committee, 1993-1994
- Quality Leadership Council, 1993-1995
- Laboratory Services Work Group (Co-chairman), 1995

Emory University School of Medicine

- Proposal Reviewer for University Research Committee, 1984, 1987
- Research Steering Committee, Emory-Industry Relations Subcommittee, 1997-1998
- Housestaff Evaluation Committee, 1985-1999

PAST STAFF AND COMMITTEE POSITIONS, GEORGIA, 1983-2001 (SELECTED) (CONT'D)

The Emory Clinic (Atlanta, Georgia)

Ad hoc Committee on Long Range Financial Planning, 1985-1987

Committee on Efficient Patient Care, 1986-1987

Telecommunications Advisory Committee, 1988-1989

Chairman, Publications Advisory Committee, 1988-1990

Administrative Committee, 1989-1990

Chairman, Computer Applications Advisory Committee, 1989-1991

Quality Assurance Committee, 1989-1995

Medical Records Committee, 1989-1990

Chief of Teaching Programs and Clinical Activities for Endocrinology and Metabolism, 1990-1998

Executive Committee, 1990-1993

Medical Informatics Committee, 1990-1994

Search Committee for Chief Information Officer, 1994

Board of Directors, Executive Committee, 1994-1995

Board of Directors Task Force, Information Services, 1995-1997

Laboratory Director, 1987-1996

Chairman, Laboratory Committee, 1987-1996

Board of Directors, 1994-1996

Associate Subsection Head, Endocrinology, 1989-1998

Chief, Osteoporosis and Metabolic Bone Diseases Program, 1985-2001

Co-director, Bone Densitometry Service, 1990-2001

RW Woodruff Health Sciences Center (Atlanta, Georgia)


HSC Research Steering Committee, Clinical and Population-Based Research Subcommittee, 1997-1998

* Steering Committee, Proposal for National Center of Excellence in Women's Health, 1997-1998

Clinical Research Restructuring Task Force, 1998-1999

**APPEARS THIS WAY
ON ORIGINAL**

COMMUNITY ACTIVITIES:



ORIGINAL ARTICLES:

1. Temple TE, **Watts NB**. Graves' disease, gastrointestinal dysfunction, and muscle weakness. *J Med Assoc Ga* 59:313-318, 1970.
2. Wheatley JK, Bennett JK, Walton KN, **Watts NB**, McNair O, O'Brien DP. Non-metastatic bladder cancer associated with hypercalcemia, thrombocytosis, and leukemoid reaction. *J Urol* 135:47-48, 1986.
3. **Watts NB**. Carcinoma metastatic to the thyroid: Prevalence, and diagnosis by fine-needle aspiration cytology. *Am J Med Sci* 1987;293:13-17.
4. **Watts NB**, Gebhart SSP, Clark RV, Phillips LS. Postoperative management of diabetes mellitus: "steady state" glucose control with a bedside algorithm for insulin adjustment. *Diabetes Care* 1987;10:722-727.
5. **Watts NB**, Tindall GT. Rapid assessment of corticotropin reserve after pituitary surgery. *JAMA* 1988;259:708-711.
7. **Watts NB**, Sewell CW. Thyroid carcinoma presenting as subacute thyroiditis. *Am J Med Sci* 1988;296:126-128.
8. **Watts NB**. Utility of an ultrasensitive assay for thyroid stimulating hormone for monitoring treatment with thyroid hormone. *Arch Intern Med*, 1989;149:309-312.
9. Walker BF, Gunthel CJ, Bryan JA, **Watts NB**, Clark RV. Disseminated cryptococcosis in an apparently normal host presenting as primary adrenal insufficiency. *Am J Med* 1989;86:715-717.
10. Gebhart SSP, **Watts NB**, Clark RV, Umpierrez G, Sgoutas D. Profound gonadotropin suppression in critical illness. *Arch Intern Med*, 1989;149:1637-1641.
11. Kolla I, Alazraki N, **Watts NB**. Sialadenitis mimicking metastatic thyroid carcinoma. *Clin Nucl Med* 1989;14:433-435.
12. Siddiq YK, **Watts NB**, Takei Y, Tindall GT. TSH-secreting pituitary tumor. *Emory U J Med* 1989;3:260-263.
13. Tindall GT, Herring CJ, Clark RV, Adams DA, **Watts NB**. Cushing's disease: Results of transsphenoidal microsurgery with emphasis on surgical failures. *J Neurosurg* 1990;72:363-369.
14. **Watts NB**, Spanheimer RG, DiGirolamo M, Gebhart SSP, Musey VC, Siddiq YK, Goldstein S, Phillips LS. Prediction of glucose response to weight loss in patients with noninsulin-dependent diabetes mellitus. *Arch Intern Med* 1990;150:803-806.
15. **Watts NB**, DiGirolamo M. Short-term fasting improves glucose tolerance and insulin action in noninsulin-dependent diabetes mellitus. *Am J Med Sci* 1990;299:250-256.
16. **Watts NB**, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. *N Engl J Med* 1990;323:73-79.
17. **Watts NB**, Clark RV, Watts RL, Graham SD, Bakay RAE. Changes in endocrine function after adrenal medullary transplantation to the central nervous system. *J Clin Endocrinol Metab* 1990;71:773-776.
18. Bakay RAE, Watts RL, Freeman A, Iuvone PM, **Watts NB**, Graham, SD. Preliminary report on adrenal-brain transplantation for parkinsonism in man. *Stereotact Funct Neurosurg* 1990;54-55:312-323.
19. Odugbesan O, **Watts NB**. Antithyroid drug therapy in Graves' hyperthyroidism. *Emory University J Med* 1992;6:130-132.
20. Tindall GT, Oyesiku NM, **Watts NB**, Clark RV, Christy JH, Adams DA. Transsphenoidal adenectomy for growth-hormone secreting pituitary adenomas in acromegaly: outcome analysis and determinants of failure. *J Neurosurg* 1993;78:205-215.
21. Harris ST, **Watts NB**, Jackson RD, Genant HK, Wasnich RD, Ross P, Miller PD, Licata AA, Chesnut CH III. Four-year study of intermittent cyclical etidronate therapy of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. *Am J Med* 1993;95:557-567.
22. Weber CJ, Vansant J, Alazraki N, Christy J, **Watts N**, Phillips LS, Mansour K, Sewell W, McGarity WC. Value of technetium 99m sestamibi-iodine 123 imaging in reoperative parathyroid surgery. *Surgery* 1993;114:1011-1018.
23. Ott SM, Woodson GC, Huffer WE, Miller PD, **Watts NB**. Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis. *J Clin Endocrinol Metab* 1994;78:968-972.

ORIGINAL ARTICLES (CONTINUED):

24. Weintraub WS, Boccuzzi SJ, Klein JL et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. *N Engl J Med* 1994;331:1331-1337.
25. Umpierrez GE, **Watts NB**, Phillips LS. Clinical utility of beta-hydroxy butyrate determined by reflectance meter in the management of diabetic ketoacidosis. *Diabetes Care* 1995;18:137-138.
26. **Watts NB**, Notelovitz M, Timmons MC, Addison WA, Wiita B, Downey LJ. Comparison of oral estrogens and estrogens plus androgens on bone mineral density, menopausal symptoms, and lipid/lipoprotein profiles in surgical menopause. *Obstet Gynecol* 1995;85:529-537.
27. Liberman U, Weiss SR, Broll J et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. *N Engl J Med* 1995;333:1437-1443.
28. Umpierrez GU, Stiles RG, Kleinbart J, Krendel DA, **Watts NB**. Diabetic muscle infarction. *Am J Med* 1996;101:245-250.
29. Tucci JR, Tonino, RP, Emkey RD et al. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. *Am J Med* 1996;101:488-501.
30. Karpf DB, Shapiro DR, Seeman E et al. Prevention of nonvertebral fractures by alendronate: a meta-analysis. *JAMA* 1997;277:1159-1164.
31. Genant HK, Lucas J, Weiss S, Akin M, Emkey R, McNancy-Flint H, Downs R, Mortola J, **Watts N**, Yang HM, Banav N, Brennan JJ, Nolan JC. Low-dose esterified estrogen therapy: effects of bone, plasma estradiol concentrations, endometrium, and lipid levels. *Arch Intern Med* 1997;157:2609-2615.
32. Miller PD, **Watts NB**, Licata AA et al. Cyclical etidronate in the treatment of postmenopausal osteoporosis: Efficacy and safety after seven years of treatment. *Am J Med* 1997;103:468-476.
33. **Watts NB**, Becker P. Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate. *Bone* 1999;24:65-68.
34. Cummings SR, Eckert S, Krueger KA et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. *JAMA* 1999;281:2189-2197.
35. Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. *JAMA* 1999;282:637-645.
36. **Watts NB**. Understanding the Bone Mass Measurement Act. *J Clin Densitom* 1999;2:211-217.
37. Harris ST, **Watts NB**, Genant HK et al. The effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis. *JAMA* 1999;282:1344-1353.
38. Schnitzer T, Bone HG, Crepaldi G et al. Therapeutic equivalence of alendronate 70 mg once weekly and alendronate 10 mg daily in the treatment of osteoporosis. *Aging Clin Exp Res*. 2000;12:1-12.
39. Looker AC, Bauer DC, Chesnut CH III, Gundberg CM, Hochberg MD, Klee G, Kleerekoper M, **Watts NB**, Bell NH. Clinical use of biochemical markers of bone remodeling: current status and future directions. *Osteoporos Int* 2000;11:467-480.
40. Chesnut CH III, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, **Watts N**, Baylink D for the PROOF Study Group. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures study. *Am J Med* 2000;109:267-276.
41. **Watts NB**, Nolan JC, Brennan JJ, Yang H-M, for the ESTRATAB® Osteoporosis Study Group. Esterified estrogen therapy in postmenopausal women. Relationships of bone marker changes and plasma estradiol to BMD changes: a two-year study. *Menopause* 2000;7:375-382.
42. **Watts NB**, Jenkins DK, Visor JM, Casal DC, Geusens P. Comparison of bone and total alkaline phosphatase and bone mineral density in postmenopausal osteoporotic women treated with alendronate. *Osteoporos Int* 2001;12:279-288.
43. Hall WD, Pettinger M, Oberman A, **Watts NB**, Johnson KC, Paskett ED, Limacher MC, Hayes J. Risk factors for kidney stones in older women in the southern United States. *Am J Med Sci* 2001;322:1-227.

ORIGINAL ARTICLES (CONTINUED):

44. **Watts NB**, Harris ST, Genant HK. Treatment of painful vertebral fractures with percutaneous vertebroplasty or Kyphoplasty. *Osteoporos Int* 2001;12:429-437.
45. Drake WM, McClung M, Njeh CF, Genant HK, Rosen C, **Watts N**, Kendler DL. Multisite bone ultrasound measurement on North American female reference population. *J Clin Densitom* 2001;4:239-248.
46. Hodgson SF, **Watts NB**, Bilezikian JP, Clarke BL, Gray TK, Harris DW, Johnston CC, Kleerekoper M, Lindsay R, Luckey MM, McClung MR, Nankin HR, Petak SM, Recker RR. American Association of Clinical Endocrinologists 2001 Medical Guidelines for Clinical Practice for the Prevention and Management of Postmenopausal Osteoporosis. *Endocrine Practice*. 2001; 7:293-312.
47. Jan de Beur SM, Streeten EA, Civelek AC, McCarthy EF, Uribe L, Marx S, Onobrakpeya O, Raisz LG, **Watts NB**, Sharon M, Levine MA. Localisation of mesenchymal tumours by somatostatin receptor imaging. *Lancet*. 2002;359:761-763.
48. Vesper HW, Demers LM, Eastell R, Garnero P, Kleerekoper M, Robins SP, Srivastava AK, Warnick GR, **Watts NB**, Myers GL. Assessment and recommendations on factors contributing to preanalytical variability of urinary pyridinoline and deoxypyridinoline. *Clinical Chemistry*. 2002;48:220-235.

**APPEARS THIS WAY
ON ORIGINAL**

REVIEWS, EDITORIALS, LETTERS:

1. **Watts NB.** Testing for Cushing's syndrome. *Laboratory Medicine*, 6:45-49, 1975.
2. **Watts NB.** The glucose tolerance test: nondiagnostic. *Lab '79*, 2:28-33, 1979.
3. **Watts NB.** Glucose tolerance testing may be done too fast. *Lab World*, 32:68-72, 1981.
4. **Watts NB.** Thyrotropin-releasing hormone. *Advanced Clinical Chemistry Check Sample*, 10:1-11, 1981.
5. **Watts NB.** Diabetes mellitus: diagnostic and monitoring techniques. *Laboratory Management*, 20:43-55, 1982.
6. **Watts NB.** Laboratory tests for monitoring thyroid hormone treatment. *Clinical Pharmacology Check Sample*, 3:1-11, 1983.
7. **Watts NB.** Solitary thyroid nodules: an overview, with emphasis on the use of fine needle aspiration cytology. *J Med Assoc Ga* 74:710-714, 1985.
8. **Watts NB, Clark RV.** Endocrinologic testing in patients with pituitary tumors. *Contemp Neurosurg* 7/17:1-6, 1985.
9. **Watts NB.** Pituitary dysfunction: clinical effects and hormone assays. *Laboratory Management* 1986;24:53-60.
10. **Watts NB.** Assessment of adrenal reserve. *Clinical Chemistry Check Sample*, 26:1-6, 1986.
11. **Watts NB.** Medical relevance of laboratory testing: A clinical perspective. *Arch Pathol Lab Med* 1988;112:379-382.
12. **Watts NB.** Suppressive therapy with levothyroxine for solitary thyroid nodules (letter). *N Engl J Med* 1987;317:1663.
13. **Watts NB.** Osteoporosis. *Am Fam Phys* 1988;38:193-207.
14. **Watts NB.** Lessons from a patient with a thyroid nodule. *Emory U J Med* 1988;2:64-70.
15. **Watts NB** (book review). *THE PITUITARY GLAND* by CR Kannan. *JAMA* 1989;261:625-626.
16. **Watts NB.** Perioperative glucose control in diabetic patients: strategies for the 1990s (editorial). *West J Med* 1989;151:552-553.
17. **Watts NB.** Diabetes mellitus: Screening and diagnosis. *ASCP Clinical Chemistry Check Sample* (89-9) 1989;29:1-5.
18. **Watts NB.** Individualized goal setting for diabetic control (letter). *Diabetes Care* 1990;13:811-812.
19. **Watts NB, Chesnut CH III, Heaney RP, Miller PD.** Osteoporosis: Its prevention, diagnosis, and treatment. *Medical Times* 1990;118:39-45.
20. **Watts NB, Chesnut CH III.** Cyclical etidronate treatment of osteoporosis (letter). *N Engl J Med* 1990;323:1634.
21. **Watts NB, Chesnut CH III, Heaney RP, Miller PD.** Osteoporosis: Its prevention, diagnosis, and treatment. *Resident & Staff Physician* 1990;36:64-70.
22. **Watts NB.** Prevention of osteoporosis: the role of primary physicians (editorial). *J Fam Pract* 1991;32:261-263.
23. **Watts NB.** Albuminuria and diabetic nephropathy: an evolving story (editorial). *Clin Chem* 1991;37:2027-2028.
24. **Watts NB.** Bisphosphonate therapy for postmenopausal osteoporosis. *South Med J* 1992;85:2S31-2S33.
25. **Watts NB.** Bedside monitoring of blood glucose monitoring in hospitals: Speed vs. precision and accuracy (editorial). *Arch Pathol Lab Med* 1993;117:1078-1079.
26. **Watts NB.** Osteoporosis: Methods to prevent fractures in patients at high risk. *Postgrad Med* 1994;95:73-88.
27. **Watts NB, Blevins LS Jr.** Endocrinology (annual "Contempo" issue). *JAMA* 1994;271:1666-1667.
28. **Watts NB.** Bisphosphonate therapy for osteoporosis. *Rheum Clin N America* 1994;20:717-734.
29. **Watts NB.** Therapy of osteoporosis: Current agents and future possibilities. *Osteoporosis Japan* 1994;2:49-57.
30. **Watts NB.** Cushing's syndrome: an update. *Contemporary Neurosurgery* 1995;17:1-8.
31. **Watts NB.** Reproducibility (Precision) in alternate site testing" a clinician's perspective. *Arch Pathol Lab Med* 1995;119:914-917.
32. **Miller PD, Bonnick SL, Rosen C, Altman RD, Avioli LV, Dequeker J, Felsenberg D, Genant HK, Gennari C, Harper KD, Hodsman AB, Kanis JA, Kleerekoper M, Mautalen CA, McClung MR, Meunier PJ, Nelson DA, Peel NFA, Raisz LG, Recker RR, Utian WH, Wasnich RD, Watts NB.** Guidelines for the clinical utilization of bone mass measurement in the adult population. *Calcif Tiss Int* 1995;57:251-252.

REVIEWS, EDITORIALS, LETTERS (CONTINUED):

33. Hodgson SF, Johnston CC, Avioli LV, Heath HH III, Khosla S, Kleerekoper M, Lindsay R, Lufkin EG, Riggs BL, **Watts NB**. AACE clinical practice guidelines for the prevention and treatment of postmenopausal osteoporosis. *Endocrine Practice* 1996;2:155-171
34. Miller PD, Bonnick SL, Rosen C, Altman RD, Avioli LV, Dequeker J, Felsenberg D, Genant HK, Gennari C, Harper KD, Hodsman AB, Kleerekoper M, Mautalen CA, McClung MR, Meunier PJ, Nelson DA, Peel NFA, Raisz LG, Recker RR, Utian WH, Wasnich RD, **Watts NB**. Consensus of an International Panel on the clinical utility of bone mass measurements the detection of low bone mass in the adult population. *Calcif Tiss Int* 1996;58:207-214.
35. Miller PD, Bonnick SL, Rosen C, Altman RD, Avioli LV, Dequeker J, Felsenberg D, Genant HK, Gennari C, Harper KD, Hodsman AB, Kleerekoper M, Mautalen CA, McClung MR, Meunier PJ, Nelson DA, Peel NFA, Raisz LG, Recker RR, Utian WH, Wasnich RD, **Watts NB**. Clinical utility of bone mass measurements in adults: Consensus of an International Panel. *Seminars Arthritis Rheumatism* 1996;361-372
36. **Watts NB**, Blevins LS Jr. Endocrinology (annual "Contempo" issue). *JAMA* 1996;275:1806-1807.
37. **Watts NB**. Osteoporosis 1996. *Am J Med Sci* 1996;312:249-250.
38. **Watts NB**. Management of Osteoporosis, 1997. *Am J Med Sci* 1997;313:1.
39. **Watts NB**. Osteoporosis: prevention, detection, and treatment. *J Med Assoc Ga* 1997;86:224-226.
40. Umpierrez GU, **Watts NB**. Diabetes, tissue infarction, and calciphylaxis. *Am J Med* 1997;102:171-172.
41. **Watts NB**. Alendronate therapy for osteoporosis. *Clinical Reviews (Southern Association for Primary Care)*. 1997;19-22.
42. Hengel, RL, **Watts NB**, Lennox JL. Benign symmetric lipomatosis associated with protease inhibitors (letter). *Lancet* 1997;350:1596.
43. Lindsay R, **Watts N**, Shoupe D. Current approaches to osteoporosis prevention. *Am J Managed Care* 1998;4 (suppl):S64-S69.
44. Consensus statement. Treatment of estrogen deficiency symptoms in women surviving breast cancer. *J Clin Endocrinol Metab* 1998;83:1993-2000.
45. **Watts NB**. Preface, Osteoporosis. *Endo Metab Clinics North America* 1998;27:xi-xii
46. **Watts NB**. Treatment of osteoporosis with bisphosphonates. *Endo Metab Clinics North America* 1998;27:419-439.
47. Bracker MD, **Watts NB**. How to get the most out of bone densitometry. *Postgrad Med* 1998;104:77-86.
48. **Watts N**. Prevention of osteoporosis with bisphosphonates in breast cancer survivors. *Obstet Gynecol Survey* 1998;53 (suppl):S40-S43.
49. **Watts NB**. Bisphosphonates for osteoporosis treatment and prevention, in *Treatment of Estrogen Deficiency Symptoms in Women Surviving Breast Cancer*, *Oncology* 1999;12:397-404.
50. **Watts N**, Freedholm D, Daifotis A. The clinical tolerability profile of alendronate. *Int J Clin Pract* 1999;(suppl 101):51-61.
51. **Watts NB**. Clinical utility of biochemical markers of bone remodeling. *Clin Chem* 1999;45:1359-1368.
52. **Watts NB**. Postmenopausal osteoporosis. *Obstet Gynecol Survey* 1999;54:532-538.
53. Miller PD, Baran DT, Bilezikian JP, Greenspan SL, Lindsay R, Riggs BL, **Watts NB**. Practical clinical application of biochemical markers of bone turnover. *J Clin Densitom* 1999;2:323-32.
54. **Watts NB**, Miller PD. Markers should be used as adjunct to bone density (letter). *Brit Med Journal* 1999;319:1371.
55. **Watts NB**. Treatment of postmenopausal osteoporosis. *J Florida Med Assn* 2000;86:8-10.
56. **Watts NB**. Using bone mineral density T-scores to diagnose postmenopausal osteoporosis (editorial). *Endocrine Pract* 2000;6:217-218.
57. Greenspan SL, Harris ST, Bone H, Miller PD, Orwoll ES, **Watts NB**, Rosen CJ. Bisphosphonates: safety and efficacy in the treatment and prevention of osteoporosis. *American Family Physician* 2000;61:2731-2736.

REVIEWS, EDITORIALS, LETTERS (CONTINUED):

58. **Watts NB.** Focus on primary care postmenopausal osteoporosis: an update. *Obstet Gynecol Surv* 2000;55 (suppl 3):S49-S55.
59. **Watts NB.** Observational data do not establish cause and effect (letter). *Arch Intern Med* 2001;161:772.
60. **Watts NB.** Treatment of osteoporosis with bisphosphonates. *Rheum Dis Clin North America* 2001;27:197-214.
61. Lenchik L, **Watts NB.** Regression to the mean: What does it mean? Using bone density results to monitor treatment of osteoporosis. *J Clin Densitom* 2001;4:1-44.
62. **Watts NB.** Risedronate for the prevention and treatment of postmenopausal osteoporosis: results from recent clinical trials. *Osteoporos Int* 2001;12:S17-S22.
63. **Watts NB.** Screening for osteoporosis in early menopause. *Sem.Arthritis Rheum.* 2002; 31: 284-285.
64. **Watts NB.** Therapies to improve bone mineral density and reduce the risk of fracture: clinical trial results. *Journal of Reproductive Medicine* 2002; 47 (suppl 1): 82-92.
65. Compston JE, **Watts NB.** Combination therapy for postmenopausal osteoporosis. *Clinical Endocrinology* 2002;56:565-569.
66. **Watts NB.** Osteoporosis 2002: Headline News. *Southern Med J* 2002;95:570-577.
67. **Watts NB.** Bisphosphonates, statins, osteoporosis, and atherosclerosis. *Southern Med J* 2002;95:578-582.
68. **Watts NB.** Bone quality: getting closer to a definition (editorial). *J Bone Miner Res* 2002;17:148-150.
69. Papaioannou A, **Watts NB.** Kendler DL. Yuen CK. Adachi JD. Ferko N. Diagnosis and management of vertebral fractures in elderly adults. *Am J Med* 2002;113:220-228.
70. **Watts NB.** Lessons from the Women's Health Initiative (editorial). *South Med J* 2002;95:952-955.

**APPEARS THIS WAY
ON ORIGINAL**

BOOKS:

1. Keffer JH, **Watts NB**. MODERN SOLUTIONS TO COMMON ENDOCRINOLOGIC PROBLEMS: A MANUAL OF HORMONE MEASUREMENT AND ENDOCRINE DIAGNOSIS. Precision Diagnostics Press, Asheville, NC, 1975.
2. **Watts NB**, Keffer JH. PRACTICAL ENDOCRINE DIAGNOSIS. Lea and Febiger, Philadelphia, 1978.
3. **Watts NB**, Keffer JH. PRACTICAL ENDOCRINE DIAGNOSIS (third edition). Lea and Febiger, Philadelphia, 1982.
4. **Watts NB**, Keffer JH. DIAGNOSTICO ENDOCRINOLOGICO PRACTICO, Intermedica, Buenos Aires, 1983.
5. **Watts NB**, Gebhart SSP (eds), EMORY UNIVERSITY HOSPITAL DIABETES MANUAL; private publication, 1985.
6. **Watts NB**. DISORDERS OF GLUCOSE METABOLISM. ASCP Press, Chicago, 1987.
7. **Watts NB**, Keffer JH. PRACTICAL ENDOCRINOLOGY (fourth edition). Lea & Febiger, Philadelphia. 1989.
8. **Watts NB** and others, section editors, Hurst JW (editor-in-chief). MEDICINE FOR THE PRACTICING PHYSICIAN (third edition), Butterworths, Stoneham, MA. 1992.
9. Lorrain J, Plouffe L, Ravnkar V, Speroff L, **Watts NB** (eds), COMPREHENSIVE MANAGEMENT OF MENOPAUSE. Springer Verlag, New York. 1993.
10. **Watts NB** and Gebhart SSP, section editors, Endocrinology and Metabolic Diseases, in Hurst JW (editor-in-chief). MEDICINE FOR THE PRACTICING PHYSICIAN (fourth edition), Appleton & Lange, Stamford, CT. 1996.

BOOK CHAPTERS:

1. Caraway WT, **Watts NB**. "Carbohydrates", pp. 775-828, in Tietz NW (ed), TEXTBOOK OF CLINICAL CHEMISTRY (third edition), WB Saunders Co., Philadelphia, 1986.
2. Chatteraj SC, **Watts NB**. "Endocrinology", pp. 997-1171, in Tietz NW (ed), TEXTBOOK OF CLINICAL CHEMISTRY (third edition), WB Saunders Co., Philadelphia, 1986.
3. Caraway WT, **Watts NB**. "Carbohydrates", pp. 422-447, in Tietz NW (ed), FUNDAMENTALS OF CLINICAL CHEMISTRY, WB Saunders Co., Philadelphia, 1987
4. Chatteraj SC, **Watts NB**. "Endocrinology", pp. 533-613, in Tietz NW (ed), FUNDAMENTALS OF CLINICAL CHEMISTRY, WB Saunders Co., Philadelphia, 1987
5. Siddiq YK and **Watts NB**. "The Adrenal Cortex", pp. 301-305, in Lubin MF, Walker HK, Smith RB (eds). MEDICAL MANAGEMENT OF THE SURGICAL PATIENT, second edition, Butterworths, Stoneham, MA. 1988.
6. Siddiq YK and **Watts NB**. "Pheochromocytoma", pp. 305-308, in Lubin MF, Walker HK, Smith RB (eds). MEDICAL MANAGEMENT OF THE SURGICAL PATIENT, second edition, Butterworths, Stoneham, MA. 1988.
7. **Watts NB**, Tindall GT. "Acromegaly and Pituitary Gigantism", pp. 505-508, in Hurst JW (ed). MEDICINE FOR THE PRACTICING PHYSICIAN (second edition), Butterworths, Stoneham, MA. 1988.
8. **Watts NB**. "Congenital Adrenal Hyperplasia", pp. 487-492, in Hurst JW (ed). MEDICINE FOR THE PRACTICING PHYSICIAN (second edition), Butterworths, Stoneham, MA. 1988.
9. **Watts NB**. "Cushing's Syndrome", pp. 454-457, in Hurst JW (ed). MEDICINE FOR THE PRACTICING PHYSICIAN (second edition), Butterworths, Stoneham, MA. 1988.
10. **Watts NB**. "Ovarian Failure", pp. 497-499, in Hurst JW (ed). MEDICINE FOR THE PRACTICING PHYSICIAN (second edition), Butterworths, Stoneham, MA. 1988.
11. **Watts NB**. "Turner's Syndrome", pp. 499-501, in Hurst JW (ed). MEDICINE FOR THE PRACTICING PHYSICIAN (second edition), Butterworths, Stoneham, MA. 1988.
12. **Watts NB**. Nonhormonal treatment of menopause, pp 17-20, in Notelovitz M (ed) MANAGING THE MENOPAUSE: AN UPDATE. New York, McGraw-Hill, 1989.
13. **Watts NB**. Endocrine Tests, in Tietz NB (ed). CLINICAL GUIDE TO LABORATORY TESTS (2nd edition), WB Saunders, Philadelphia, 1990.

BOOK CHAPTERS (CONTINUED):

14. **Watts NB.** A physician's perspective on the total testing process. in Martin ML, Addison BV, Wagner WM, Essien JDK (eds). PROCEEDINGS OF THE 1989 INSTITUTE ON CRITICAL ISSUES IN HEALTH LABORATORY PRACTICE, Centers for Disease Control, Atlanta, 1991.
15. Wheaton RN, **Watts NB**, Mullins RE. Diabetes mellitus: strategies for diagnosis and monitoring of metabolic control in Wu AHB (ed), CLINICAL CHEMISTRY, American Association of Clinical Chemistry, Health Education Resources, Bethesda, Maryland, 1991.
16. Free HM, Baker J, Haber MH, ... **Watts NB.** ROUTINE URINALYSIS: PROPOSED GUIDELINES. National Committee for Clinical Laboratory Standards, Lancaster, PA, Document GP16-P, 1991.
17. **Watts NB**, Tindall GT. "Acromegaly and Pituitary Gigantism", pp. 510-513, in Hurst JW (ed). MEDICINE FOR THE PRACTICING PHYSICIAN (third edition), Butterworths, Stoneham, MA. 1992.
18. **Watts NB.** "Congenital Adrenal Hyperplasia", pp. 525-529, in Hurst JW (ed). MEDICINE FOR THE PRACTICING PHYSICIAN (third edition), Butterworths, Stoneham, MA. 1992.
19. **Watts NB.** "Cushing's Syndrome", pp. 518-522, in Hurst JW (ed). MEDICINE FOR THE PRACTICING PHYSICIAN (third edition), Butterworths, Stoneham, MA. 1992.
20. **Watts NB.** "Ovarian Failure and Turner's Syndrome," pp. 565-568, in Hurst JW (ed). MEDICINE FOR THE PRACTICING PHYSICIAN (third edition), Butterworths, Stoneham, MA. 1992.
21. **Watts NB.** "Clinical Assessment for Osteoporosis and Osteopenia" pp. 110-116, in Lorrain J, Plouffe L, Ravnika V, Speroff L, **Watts NB** (eds), COMPREHENSIVE MANAGEMENT OF MENOPAUSE. Springer Verlag, New York. 1993, pgs 110-116.
22. **Watts NB.** "Calcitonin, Bisphosphonates, and Miscellaneous Agents for Treatment of Osteoporosis" in Lorrain J, Plouffe L, Ravnika V, Speroff L, **Watts NB** (eds), COMPREHENSIVE MANAGEMENT OF MENOPAUSE. Springer Verlag, New York. 1993, pgs 177-184.
23. **Watts NB.** "Selection of the Best Treatment for Osteoporosis" in Lorrain J, Plouffe L, Ravnika V, Speroff L, **Watts NB** (eds), COMPREHENSIVE MANAGEMENT OF MENOPAUSE. Springer Verlag, New York. 1993, pgs 193-200.
24. **Watts NB.** "Complicated and Controversial Considerations Regarding Estrogen Therapy" in Lorrain J, Plouffe L, Ravnika V, Speroff L. **Watts NB** (eds), COMPREHENSIVE MANAGEMENT OF MENOPAUSE. Springer Verlag, New York. 1993, pgs 395-397.
25. Whitley RJ, Meikle AW, **Watts NB.** "Endocrinology" in Burtis CA, Ashwood ER (eds). TIETZ TEXTBOOK OF CLINICAL CHEMISTRY (fourth edition), WB Saunders Co., Philadelphia, 1993, pgs 1645-1886.
26. **Watts NB,** "The Anterior Pituitary" in Noe DA, Rock RC (eds), LABORATORY MEDICINE: THE SELECTION AND INTERPRETATION OF CLINICAL LABORATORY STUDIES, Williams and Wilkins. Baltimore. 1993, pgs 618-628.
27. **Watts NB,** "Bisphosphonates" in Zichella L, Valente M, Perrone G (eds), MENOPAUSA E QUALITA DELLA VITA PER LA TERZA ETA (MENOPAUSE AND QUALITY OF LIFE IN THE MATURE YEARS. Monduzzi Editore SpA, Bologna, 1994, pgs 303-310.
28. Whitley RJ, Meikle AW, **Watts NB.** "Endocrinology" in Burtis CA, Ashwood ER (eds), TIETZ FUNDAMENTALS OF CLINICAL CHEMISTRY (fourth edition), WB Saunders Co., Philadelphia. 1996. pgs 617-684.
29. NCCLS. Urinalysis and collection, transportation, and preservation of urine specimens; approved guideline. National Committee for Clinical Laboratory Standards, Wayne, PA, Document GP16-A, 1995.
30. **Watts NB**, Tindall GT. "Acromegaly and Pituitary Gigantism", pp. 549-552, in Hurst JW (ed). MEDICINE FOR THE PRACTICING PHYSICIAN (fourth edition). Appleton & Lange, Stamford, CT. 1996.
31. **Watts NB.** "Cushing's Syndrome", pp. 558-563, in Hurst JW (ed). MEDICINE FOR THE PRACTICING PHYSICIAN (fourth edition), Appleton & Lange, Stamford, CT. 1996.

.BOOK CHAPTERS (CONTINUED):

32. **Watts NB.** "Congenital Adrenal Hyperplasia", pp. 566-570, in Hurst JW (ed). **MEDICINE FOR THE PRACTICING PHYSICIAN** (fourth edition), Appleton & Lange, Stamford, CT, 1996
33. **Watts NB.** "Ovarian Failure and Turner's Syndrome", pp. 610-613, in Hurst JW (ed). **MEDICINE FOR THE PRACTICING PHYSICIAN** (fourth edition). Appleton & Lange, Stamford, CT, 1996.
34. **Watts NB.** "Pharmacologic Therapy for Osteoporosis", pp. 99-108, in Kleerekoper M, Siris E, McClung M (eds), **BONE AND MINERAL MANUAL**, Academic Press, San Diego, CA, 1999.
35. **Watts NB.** "Pharmacology of Agents to Treat Osteoporosis," pp 278-283, Favus MJ (ed), **PRIMER ON THE METABOLIC BONE DISEASES AND DISORDERS OF MINERAL METABOLISM**, Lippincott Williams & Wilkins, Philadelphia, 1999.
36. **Marcus R and Watts NB.** "Estrogen-dependent Bone Loss and Osteoporosis," pp 73-83, in Korenman G (ed), **ATLAS OF CLINICAL ENDOCRINOLOGY. Volume III. OSTEOPOROSIS**, (Marcus R volume editor), Current Medicine, Inc., Philadelphia, 2000.
37. **Watts NB.** "Antiresorptive Therapies of Osteoporosis," pp 161-168, in Korenman G (ed), **ATLAS OF CLINICAL ENDOCRINOLOGY, Volume III, OSTEOPOROSIS**, (Marcus R volume editor), Current Medicine, Inc., Philadelphia, 2000.
38. **Watts NB.** "Bisphosphonate Treatment for Osteoporosis," pp 121-132, in Avioli LV (ed), **THE OSTEOPOROTIC SYNDROME** (fourth edition), Academic Press, San Diego, 2000.
39. **Watts NB.** "Bone Markers for Monitoring Osteoporosis," pp 187-196, in Eastell R, Baumann M, Hoyle NR, Wicczorek L (eds), **BONE MARKERS: BIOCHEMICAL AND CLINICAL PERSPECTIVE**. Martin Dunitz Ltd, London, 2001.
40. **Watts NB.** "Osteoporosis Treatment," pp 523-527, in Klippel JH ed, **PRIMER ON THE RHEUMATIC DISEASES**, Arthritis Foundation, Atlanta, 2001.
41. **Watts NB.** Bisphosphonate Treatment of Osteoporosis, pp 459-474 in Orwoll ES and Bliziotes M, **OSTEOPOROSIS: PATHOPHYSIOLOGY AND CLINICAL MANAGEMENT**, Humana Press Totowa, NJ, 2002.

**APPEARS THIS WAY
ON ORIGINAL**

ABSTRACTS:

1. **Watts NB.** Fine needle aspiration (FNA) cytology in the diagnosis of carcinoma metastatic to the thyroid. Clin Res 32:838A, 1984. Presented at the American Federation for Clinical Research, New Orleans, January 31, 1985.
2. **Watts NB.** Fine needle aspiration (FNA) cytology in the diagnosis of carcinoma metastatic to the thyroid. Presented at the Southeastern Regional Endocrine Group, Atlanta, April 19, 1985.
3. **Watts NB.** AM plasma cortisol is an indicator of adrenal reserve after pituitary surgery. Presented at the Southeastern Regional Endocrine Group, Augusta, GA, November 8, 1985.
4. **Watts NB, Tindall GT.** Early assessment of adrenal reserve after pituitary surgery. Clin Res 34:181A, 1986.
5. **Watts NB, Gebhart SSP, Clark RV.** Postoperative management of diabetes mellitus using combined infusion of insulin and dextrose. Clin Res 34:198A, 1986. Presented at the American Federation for Clinical Research, Southern Section, New Orleans, February 7, 1986.
6. **Gebhart SSP, Clark RV, Watts NB, Sgoutas D.** Profound gonadotropin suppression in critical illness. Clin Res 34:179A, 1986. Presented at the American Federation for Clinical Research, Southern Section, New Orleans, February 7, 1986.
7. **Spanheimer RG, DiGirolamo M, Watts NB, Musey VC, Siddiq YK, Gebhart SSP, Goldstein S, Davidson JK, Phillips LS.** Glycemic response to weight loss in obese diabetic patients. Clin Res 34:179A, 1986. Presented at the American Federation for Clinical Research, Southern Section, New Orleans, February 7, 1986.
8. **Spanheimer RG, DiGirolamo M, Watts NB, Musey VC, Siddiq YK, Gebhart SSP, Goldstein S, Davidson JK, Phillips LS.** Glycemic response to weight loss in obese diabetic patients. Diabetes 35 (suppl 1):46A, 1986. Presented at the annual meeting of the American Diabetes Association, Anaheim, June 24, 1986.
9. **Watts NB, Gebhart SSP, Clark RV.** A bedside algorithm for insulin infusion in the postoperative management of diabetes mellitus. Diabetes 35 (suppl 1):119A, 1986.
10. **Watts NB, Tindall GT.** Assessment of pituitary-adrenal reserve after transsphenoidal surgery. Presented at The Endocrine Society, 68th Annual Meeting, Anaheim, June 27, 1986 (p 177).
11. **Meyer KE, DePuey EG, McGarity WC, Watts NB, Gober AM.** Clinical validation of parathyroid imaging using peak TL-201 activity images and an image reregistration technique. J Nuclear Med 1986;27:963. Presented at the 33rd Annual Meeting, Society of Nuclear Medicine, San Diego, June, 1986.
12. **Watts NB.** Utility of an ultrasensitive assay for thyroid stimulating hormone for monitoring thyroid hormone treatment. Clin Res 1987;35:12a. Presented at the American Federation for Clinical Research, New Orleans, January 29, 1987.
13. **Watts NB, DiGirolamo M.** Short-term fasting improves insulin action and glucose tolerance in noninsulin-dependent diabetes mellitus. Clin Res 1987;35:26a. Presented at the American Federation for Clinical Research, Southern Section, New Orleans, January 29, 1987.
14. **Watts NB, DiGirolamo M.** Short-term fasting improves glucose tolerance and insulin action in noninsulin-dependent diabetes mellitus. Diabetes 1987;36 (suppl 1):213a.
15. **Watts NB.** Utility of an ultrasensitive assay for thyroid stimulating hormone for monitoring thyroid hormone treatment. Clin Res 1987;35:403a.
16. **Watts NB.** Utility of an ultrasensitive assay for thyroid stimulating hormone for monitoring thyroid hormone treatment. Presented at the American Thyroid Association Annual Meeting, Washington, DC, June 23, 1987.
17. **Watts RL, Bakay RAE, Iuvone PM, Watts NB, Graham S.** Autologous adrenal-caudate transplantation in patients with Parkinson's disease. Presented at the American Association of Neurology Annual Meeting, Cincinnati, April 19, 1988.
18. **Watts NB, Musey VC, Fekete P, Sewell CW, McGarity WC.** Caveat on the diagnosis of follicular thyroid neoplasms by fine needle aspiration cytology. Clin Res 1989;37:12a. Presented at the American Federation for Clinical Research, Southern Section, New Orleans, February 1, 1989.

ABSTRACTS (CONTINUED):

19. **Watts NB**, Clark RV, Watts RL, Bakay, RAE. Endocrine function after adrenal medullary transplantation to the central nervous system. Clin Res 1989;37:12a. Presented at the American Federation for Clinical Research, Southern Section, New Orleans, February 2, 1989
20. **Watts NB**, Woodson GC III, O'Neal S, Catherwood BD. Serum bone gamma-carboxyglutamate-containing protein (BGP) declines with time after menopause by does not correlate with age. Clin Res 1989;37:22a. Presented at the American Federation for Clinical Research, Southern Section, New Orleans, February 2, 1989
21. Clark RV, **Watts NB**, Watts RL, Graham SD, Bakay RA. Fall in testicular and adrenal androgens after adrenal medullary transplant for Parkinson's disease. Presented at the Annual Meeting of the American Society of Andrology, April 14, 1989.
22. Watts RL, Freeman A, Bakay RAE, Iuvone M, **Watts N**, Graham S. Adrenal-caudate transplantation in patients with Parkinson's disease (PD): 1 year follow-up. Neurology 1989;39:Suppl1:27.
23. Tindall GT, Herring C, **Watts NB**, Clark R. Transsphenoidal surgery for Cushing's disease. Presented at the Second International Pituitary Congress, Palm Springs, CA, June 25, 1989
24. Tindall GT, Christy JH, **Watts NB**, Oyesiku NM, Adams D. Transsphenoidal microsurgical adenomectomy of growth hormone-secreting tumors: Surgical results in 94 patients. Presented at the Second International Pituitary Congress, Palm Springs, CA, June 25, 1989.
25. **Watts NB**. Screening and diagnosis of diabetes mellitus. American Association for Clinical Chemistry, 41st Annual Meeting, Atlanta, GA, July 26, 1989.
26. **Watts NB**, Woodson GC III, O'Neal S, Catherwood BD. Serum bone gamma-carboxyglutamate-containing protein (BGP) declines with time after menopause by does not correlate with age. J Bone Min Res 1989;4:S172. Presented at the Tenth International Conference on Calcium Regulating Hormones and Eleventh Annual Meeting of the American Society for Bone and Mineral Research, Montreal, Canada, September 9, 1989.
27. Licata A, Jackson R, Miller P, **Watts N**, Harris S, Genant H, Wasnich R, Chesnut C. The effects of cyclical etidronate with or without phosphate in the treatment of postmenopausal osteoporosis: results of a multicenter study. J Bone Min Res 1989;4:S378. Presented at the Tenth International Conference on Calcium Regulating Hormones and Eleventh Annual Meeting of the American Society for Bone and Mineral Research, Montreal, Canada, September 14, 1989.
28. Birdsong GG, Fekete PS, **Watts NB**. Fine needle aspiration of colloid nodule vs follicular neoplasm: a semiquantitative comparison in 21 cases. Presented at the annual meeting, American Society of Cytology, Louisville, KY, November, 1989.
29. **Watts NB**, Baillie EE, Keffer JH. Undiagnosed thyroid dysfunction in hospitalized patients: Detection with a sensitive assay for thyrotropin. Clin Res 1990;36:9A. Presented at the American Federation for Clinical Research, Southern Section, New Orleans, January 18, 1990
30. Odugbesan AO, **Watts NB**. Long term remissions with antithyroid drug therapy are uncommon in Graves' disease. Clin Res 1990;36:8A. Presented at the American Federation for Clinical Research, Southern Section, New Orleans, January 18, 1990
31. Miller P, **Watts N**, Genant H, Wasnich R, Jackson R, Licata A, Chesnut C. The effects of cyclical etidronate on bone mass and fracture rate in postmenopausal osteoporosis: a three-year study. Presented at the Third International Symposium on Osteoporosis, Copenhagen, Denmark, October 17, 1990, published in Osteoporosis 1990, Osteopres ApS, Copenhagen. 1990, pages 1403-1440.
32. Mayur N, Nassar VH, **Watts NB**. Thyroid nodule masquerading as a parathyroid adenoma. Clin Res 1990;38:988A.
33. **Watts NB**, Genant HK, Harris ST et al. Clinical correlates of radiographically apparent vertebral fractures. Presented at the 22nd European Symposium on Calcified Tissues, Vienna, Austria, March 11, 1991. Calcif Tiss 1991;48 (suppl):A39.

ABSTRACTS (CONTINUED):

34. **Watts NB**, Hewan-Lowe K. "Burned-out" Paget's disease confused with metastatic carcinoma. Presented at the 1991 Annual Meeting of the Adult Bone and Mineral Working Group, American Society of Bone and Mineral Research, San Diego, August 25, 1991. *J Bone Mineral Res* 1991;6 (suppl 1):S305.
35. Ott SM, Woodson GC, Huffer WE, Miller PD, **Watts NB**. Effects of etidronate and phosphate on bone histomorphometry in women with postmenopausal osteoporosis. Presented at the 1991 Annual Meeting of the American Society of Bone and Mineral Research, San Diego, August 26, 1991. *J Bone Mineral Res* 1991;6 (suppl 1):S224.
36. **Watts NB**, Notelovitz M, Timmons C, Addison WA, Wiita B, Downey L. Estrogen alone combined with estrogen plus androgen: effects of therapy on bone mineral density and serum lipids and lipoproteins. Presented at the 1991 Annual Meeting of the American Society of Bone and Mineral Research, San Diego, August 27, 1991. *J Bone Mineral Res* 1991;6 (suppl 1):S279.
37. Notelovitz M, **Watts N**, Timmons C, Addison A, Wiita B, Downey L. Influence of extended treatment with oral estrogens/androgen combination on lipids and lipoproteins in surgically menopausal women. Presented at the 2nd Annual Meeting of the North American Menopause Society, Montreal, Canada, September 26, 1991.
38. Notelovitz M, **Watts N**, Timmons C, Addison A, Wiita B, Downey L. Effect of long-term treatment with oral esterified estrogens (estrone sulfate + equilin sulfate) on cholesterol and lipoprotein levels in postmenopausal women. Presented at the 2nd Annual Meeting of the North American Menopause Society, Montreal, Canada, September 26, 1991.
39. **Watts N**, Notelovitz M, Timmons C, Addison WA, Wiita B, Downey L. Effect oral esterified estrogens and esterified estrogens + androgen on bone mineral density in postmenopausal women. Presented at the 2nd Annual Meeting of the North American Menopause Society, Montreal, Canada, September 27, 1991.
40. Kuno HL, **Watts NB**. An unusual case of Cushing's syndrome caused by unilateral multinodular hyperplasia: an adrenal myelolipoma on the same side, and a nonfunctioning adrenal cortical carcinoma on the opposite side. *Clin Res* 1991;39:873A
41. **Watts NB**, Wasnich RD, Ross P, Jackson RD, Harris ST, Genant HK, Licata AA, Miller PD, Chesnut CH. Etidronate treatment of postmenopausal osteoporosis: experience in the U.S. Multicenter Trial. Presented at the annual meeting of the Kansei Rheumatology Association, Osaka, Japan, March 6, 1992.
42. Jackson RD, Harris ST, Genant HK, **Watts NB**, Wasnich RD, Licata AA, Miller PD, Chesnut CH III. Cyclical etidronate treatment of postmenopausal osteoporosis: 4 year experience. Presented at the XIth International Conference on Calcium Regulating Hormones, Florence, Italy, April 27, 1992.
43. Wasnich RD, Ross P, Jackson RD, Harris ST, Genant HK, **Watts NB**, Licata AA, Miller PD, Chesnut CH. A clinical trial of cyclical etidronate treatment of postmenopausal osteoporosis: four year experience. Presented at the First International Symposium and Exhibition on Osteoporosis and Metabolic Bone Diseases (Iso '92), Beijing, China, May 8-11, 1992.
44. **Watts NB**. Bisphosphonate therapy for postmenopausal osteoporosis. Presented at the 74th Annual Meeting of the Endocrine Society, San Antonio, Texas, June 27, 1992 (page 47).
45. **Watts N**, Notelovitz M, Speroff L, Timmons MC, Addison A, Wiita B, Downey LJ. Long-term safety of estrogen and low dose androgen (Estratest) vs estrogen alone (Estratab) in menopausal women. Presented at the 3rd Annual Meeting of the North American Menopause Society, Cleveland, Ohio, September 17, 1992.
46. Notelovitz M, **Watts N**, Timmons MC, Addison A, Wiita B, Downey LJ. Effects of estrogen and low dose androgen vs estrogen alone on menopausal symptoms in oophorectomized/hysterectomized women. Presented at the 3rd Annual Meeting of the North American Menopause Society, Cleveland, Ohio, September 17, 1992.
47. Chesnut CH III, Genant HK, Harris ST, Jackson RD, Licata AA, Miller PD, Ross PD, Wasnich RD, **Watts NB**. Etidronate cyclical therapy for treatment of postmenopausal osteoporosis: 4 year experience. Presented at the Fourteenth Annual Meeting of the American Society for Bone and Mineral Research, Minneapolis, September 30, 1992. *J Bone Min Res* 1992;7 (suppl 1):s143.

ABSTRACTS (CONTINUED):

48. **Watts NB**, Richard M, Gebhart SSP, El-Kebbi I, Musey V, Robertson D. Screening for diabetic nephropathy: a systematic approach in diabetic outpatients. 53rd Annual Meeting of the American Diabetes Association. *Diabetes* 1993;42 (suppl 1):109A.
49. Licata AA, Chesnut CH, Genant HK, Harris ST, Jackson RD, Ross PD, Wasnich RD, **Watts NB**. Effects of 2 years' follow-up cyclical etidronate treatment in postmenopausal osteoporotic women. Presented at the 15th Annual Meeting of the American Society for Bone and Mineral Research, Tampa, FL, September 21, 1993. *J Bone Miner Res* 1993;8 (suppl 1):S141.
50. **Watts NB**, Wuorio S. Calcitonin treatment of osteoporosis: analgesic response and side effects in clinical practice. Presented at the 15th Annual Meeting of the American Society for Bone and Mineral Research, Tampa, FL, September 21, 1993. *J Bone Miner Res* 1993;8(suppl 1):S334.
51. Umpierrez GE, **Watts NB**, Mixon PS, Phillips LS. B-hydroxybutyrate and acetoacetate levels: clinical utility in the management of diabetic ketoacidosis. *Clin Res* 1993;41:787A.
52. Miller PD, Jackson RD, Ross PD, Wasnich RD, Genant HK, Harris ST, Licata AA, **Watts NB**, Chesnut CH. ICT etidronate for osteoporosis: 5-year results. Presented at the Second Workshop on Bisphosphonates, Davos, Switzerland, April 15, 1994.
53. Santora AC, Leon J, Bell N et al. Effects of alendronate on bone mass and bone turnover in postmenopausal women. Presented at the Beijing 2nd International Symposium on Osteoporosis, October 11-16, 1994.
54. Wasnich RD, Karpf DB, Quan H et al. Three-year treatment with alendronate prevents osteoporotic fractures. Presented at the Beijing 2nd International Symposium on Osteoporosis, October 11-16, 1994.
55. Chesnut C, Genant H, Harris S, Licata A, Miller P, Wasnich R, **Watts N**, Axelrod D, Bortey E, Schoenfeld S, Sacco-Gibson N. Bone marker changes in postmenopausal women on etidronate. Presented at the XXIVth European Symposium on Calcified Tissues, Aarhus, Denmark, May 29, 1995, *Calcif Tissue Int* 1995;56:491.
56. Recker RR, Karpf DB, Quan H et al. Three-year treatment of osteoporosis with alendronate: Effect on vertebral fracture incidence. Presented at the 77th Annual Meeting of the Endocrine Society, Washington, DC, June 14, 1995 (p 49).
57. **Watts NB**, Jenkins ME. In women with postmenopausal osteoporosis, low serum levels of 25-hydroxyvitamin D are associated with lower spine bone mineral density. Presented at the 17th annual meeting of the American Society for Bone and Mineral Research, Baltimore, Maryland, September 11, 1995. *J Bone Mineral Res* 1995;10 (suppl 1):S343.
58. Hirsch L, **Watts N**, McIlwain H et al. Efficacy of alendronate to increase BMD is similar irrespective of baseline bone turnover, BMD and age. Presented at the 17th annual meeting of the American Society for Bone and Mineral Research, Baltimore, Maryland, September 11, 1995. *J Bone Mineral Res* 1995;10 (suppl 1):S350.
59. **Watts NB**. Concomitant vanishing bone disease (Gorham-Stout disease) and osteomalacia. Presented at the 17th annual meeting of the American Society for Bone and Mineral Research, Baltimore, Maryland (Adult Bone and Mineral Working Group), September 10, 1995. *J Bone Mineral Res* 1995;10 (suppl 1):S509.
60. Downs R, Baker M, Bell N et al. Three-year treatment of osteoporosis in postmenopausal women with oral alendronate: effects on bone mass and turnover, and safety. Presented at the 17th annual meeting of the American Society for Bone and Mineral Research, Baltimore, Maryland, September 10, 1995. *J Bone Mineral Res* 1995;10 (suppl 1):S139.
61. Arlot MC, Meunier PJ, Chavassieux P et al. Effects of long-term alendronate treatment for postmenopausal osteoporosis on bone histomorphometry. Presented at the 17th annual meeting of the American Society for Bone and Mineral Research, Baltimore, Maryland, September 9, 1995. *J Bone Mineral Res* 1995;10 (suppl 1):S199.
62. Shapiro DR, Thompson DE, Karpf DB et al. Non-vertebral fracture incidence in patients treated with alendronate. Presented at the 17th annual meeting of the American Society for Bone and Mineral Research, Baltimore, Maryland, September 13, 1995. *J Bone Mineral Res* 1995;10 (suppl 1):S177.

ABSTRACTS (CONTINUED):

63. Hirsch LJ, Cumming DC, Dequeker J, Favus M, Kher U, Santora AC, **Watts NB**, Yates AJ for the Alendronate Phase II Study Group. Response to alendronate is independent of the baseline rate of bone turnover. Presented at the Third Workshop on Bisphosphonates, Davos, Switzerland, January 13, 1996. *Bone* 1995;17:613.
64. **Watts NB**, Miller PD, Licata AA, Jackson RD, Wasnich RD, Ross PD, Harris ST, Genant HK, Schoenfeld SL, Valent DJ, Chesnut CH III. Seven years of cyclical etidronate: continued improvement in spine BMD and progressive decline in vertebral fracture incidence. Presented at the Third Workshop on Bisphosphonates, Davos, Switzerland, January 13, 1996. *Bone* 1995;17:617.
65. Genant H, Lucas J, Weiss S, Akin M, Emkey R, McNaney-Flint H, Downs R, Mortola J, **Watts N**, Yang H-M, Nolan J. A clinical study of 0.3, 0.625, and 1.25 mg esterified estrogens (Estratab) for the prevention of postmenopausal osteoporosis. Presented at the 1996 World Congress on Osteoporosis, Amsterdam, May 21, 1996. *Osteoporosis Int* 1996;6:228.
66. Chesnut C III, **Watts N**, Miller P, Licata A, Jackson R, Wasnich R, Ross P, Harris S, Genant H, Schoenfeld S, Valent D. Cyclical etidronate: efficacy and safety over seven years. Presented at the 1996 World Congress on Osteoporosis, Amsterdam, May 21, 1996. *Osteoporosis Int* 1996;6:257.
67. Freedholm D, Emkey R, Cummings DC, Averbuch S, Santora A, Lombardi A, Yates AH, Ng J. Safety and tolerability of oral alendronate in the treatment of postmenopausal osteoporosis. Presented at the 1996 World Congress on Osteoporosis, Amsterdam, May 21, 1996. *Osteoporosis Int* 1996;6:261.
68. Meunier PJ, Chavassieux P, Recker RR, Yates AJ. Bone histomorphometry in long-term studies of alendronate in postmenopausal women. Presented at the 1996 World Congress on Osteoporosis, Amsterdam, May 21, 1996. *Osteoporosis Int* 1996;6:261.
69. Harris ST, **Watts NB**, Hosking D, Adami S, Quan H, Shapiro D, Thompson DE, Santora AC, Karpf DB. Treatment with alendronate prevents fractures in women with postmenopausal osteoporosis. Presented at the 1996 World Congress on Osteoporosis, Amsterdam, May 21, 1996. *Osteoporosis Int* 1996;6:261.
70. Rosen CJ, Greenspan SL, Braimon J, Devreault D, Ziegler TR, **Watts NB**, Baylink DJ, Mohan S. The impact of hip fractures and hip surgery on serum IGF-I, IGFBP-4 and IGFBP-5 in elderly men and women. Presented at the 10th International Congress of Endocrinology, San Francisco, June 14, 1996 (program p. 757).
71. **Watts N**, Greenwald, M, Notelovitz M, Genant H, Lenihan J, Yang HM, Nolan J. Low dose esterified estrogens (Estratab) reduce biochemical markers of bone metabolism and increase vertebral BMD in postmenopausal women. Presented at the 18th Annual Meeting of the American Society for Bone and Mineral Research, Seattle, September 7, 1996 (plenary poster session). *J Bone Miner Res* 1996;11 (suppl 1): S153.
72. **Watts NB**. Effect of smoking on bone mineral density: findings in identical twins. Presented at the 18th Annual Meeting of the American Society for Bone and Mineral Research, Seattle, September 8, 1996. *J Bone Miner Res* 1996;11 (suppl 1): S498.
73. **Watts NB**, Jenkins ME. Multivitamin therapy corrects low serum levels of 25-hydroxyvitamin D in women with postmenopausal osteoporosis. Presented at the 18th Annual Meeting of the American Society for Bone and Mineral Research, Seattle, September 9, 1996. *J Bone Miner Res* 1996;11 (suppl 1): S226.
74. Cook F, Rosen CJ, Vereault D, Steffena C, Kessenich CR, Greenspan S, Ziegler TR, **Watts NB**, Mohan S, Baylink DJ. Major changes in the circulatory IGF regulatory system after hip fracture surgery: potential therapeutic implications. Presented at the 18th Annual Meeting of the American Society for Bone and Mineral Research, Seattle, September 9, 1996. *J Bone Miner Res* 1996;11 (suppl 1): S327.
75. **Watts NB**, Becker P. Alendronate increases bone mineral density at spine and hip in women with postmenopausal osteoporosis who fail to respond to intermittent cyclic etidronate. Plenary poster presentation at the 19th Annual Meeting of the American Society for Bone and Mineral Research, Cincinnati, September 10, 1997. *J Bone Miner Res* 1997;12 (suppl 1): S171.

ABSTRACTS (CONTINUED):

76. **Watts N**, Rebar R, Genant H et al. The relationship of plasma estradiol levels to BMD changes in a clinical study of esterified estrogens (Estratab) in postmenopausal women. Presented at the 19th Annual Meeting of the American Society for Bone and Mineral Research, Cincinnati, September 12, 1997. *J Bone Miner Res* 1997;12 (suppl 1): S352.
77. **Watts NB**. Coexistent vitamin D deficiency and primary hyperparathyroidism. Presented at the Adult Bone and Mineral Working Group, 19th Annual Meeting of the American Society for Bone and Mineral Research, Cincinnati, Sept. 12, 1997. *J Bone Mineral Res* 1997;12:S529.
78. Stock JL, Avioli LV, Baylink DJ, et al for the PROOF Study Group. Calcitonin-salmon nasal spray reduces the incidence of new vertebral fractures in postmenopausal women: three-year interim results of the PROOF study. Presented at the 19th Annual Meeting of the American Society for Bone and Mineral Research, Cincinnati, Sept. 14, 1997. *J Bone Mineral Res* 1997;12:S149.
79. Favus M, Emkey R, Leite M, et al for the Alendronate Phase III Osteoporosis Treatment Study Group. Five-year treatment of osteoporosis in postmenopausal women with oral alendronate: effects on bone mass and turnover and safety. Presented at the 19th Annual Meeting of the American Society for Bone and Mineral Research, Cincinnati, Sept. 14, 1997. *J Bone Mineral Res* 1997;12:S150.
80. **Watts NB**. A clinician's assessment of Miacalcic nasal spray for osteoporosis. Presented at the European Congress on Osteoporosis, Berlin, Germany, September 11, 1998. *Osteoporosis Int* 1998;8 (suppl 3):147.
81. Ettinger B, Black D, Cummings S et al for the MORE Study Group. Raloxifene reduces the risk of incident vertebral fractures: 24-month interim analyses. Presented at the European Congress on Osteoporosis, Berlin, Germany, September 14, 1998. *Osteoporosis Int* 1998;8 (suppl 3):11.
82. Chesnut C, Baylink DJ, Doyle D et al for the PROOF Study Group. Salmon-calcitonin nasal spray prevents vertebral fractures in established osteoporosis: further interim results of the PROOF Study. Presented at the European Congress on Osteoporosis, Berlin, Germany, September 14, 1998. *Osteoporosis Int* 1998;8 (suppl 3):13.
83. Chesnut C, Silverman SL, Andriano K et al for the PROOF Study Group. Salmon calcitonin nasal spray reduces the rate of new vertebral fractures independently of known major pre-treatment risk factors: accrued 5 year analysis of the PROOF study. Presented at the 2nd Joint Meeting of the American Society for Bone and Mineral Research and the International Bone and Mineral Society, San Francisco, December 1, 1998. *Bone* 1998;23:S290.
84. **Watts NB**, Becker P. An unusual cause for an elevated serum alkaline phosphatase level in the son of a patient with Paget's disease. Presented at the Adult Bone and Mineral Working Group, 2nd Joint Meeting of the American Society for Bone and Mineral Research and the International Bone and Mineral Society, San Francisco, December 2, 1998. *Bone* 1998;23:S645.
85. Ensrud K, Black D, Recker R et al. for the MORE Study Group. The effect of 2 and 3 years of raloxifene on vertebral and non-vertebral fractures in postmenopausal Women with Osteoporosis. Presented at 2nd Joint Meeting of the American Society for Bone and Mineral Research and the International Bone and Mineral Society, San Francisco, December 3, 1998. *Bone* 1998;23:S174.
86. Silverman SL, Chesnut C, Andriano K et al for the PROOF Study Group. Salmon calcitonin nasal spray (NS-CT) reduces risk of vertebral fracture(s) (VF) in established osteoporosis and has continuous efficacy with prolonged treatment: accrued 5 year worldwide data of the PROOF Study. Presented at 2nd Joint Meeting of the American Society for Bone and Mineral Research and the International Bone and Mineral Society, San Francisco, December 3, 1998. *Bone* 1998;23:S174.
87. **Watts N**, Hangartner T, Chesnut C et al. Risedronate treatment prevents vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. Presented at the 26th European Symposium on Calcified Tissues, Maastricht, May 10, 1999. *Calcified Tissue Int* 1999;64 (suppl 1):S42.
88. Silverman SL, Moniz C, Andriano K... **Watts N** et al. Salmon-calcitonin nasal spray prevents vertebral fractures in established osteoporosis. Final world wide results of the "PROOF" study. Presented at the 26th European Symposium on Calcified Tissues, Maastricht, May 10, 1999. *Calcified Tissue Int* 1999;64 (suppl 1):S43.

ABSTRACTS (CONTINUED):

89. Delmas PD, Ensrud KE, Harris S et al. Raloxifene therapy for 3 years reduces the risk of incident vertebral fractures in postmenopausal women. Presented at the 26th European Symposium on Calcified Tissues, Maastricht, May 10, 1999. *Calcified Tissue Int* 1999;64 (suppl 1):S43.
90. Erksen EF, Melsen F, Brown JP et al. Histology and histomorphometry in post-menopausal osteoporotic women receiving three years of risedronate treatment. Presented at the 26th European Symposium on Calcified Tissues, Maastricht, May 10, 1999. *Calcified Tissue Int* 1999;64 (suppl 1):S69.
91. **Watts NB**, Hangartner T, Chesnut C et al. Risedronate reduces osteoporotic fractures in postmenopausal women. Presented at the 81st Annual Meeting of the Endocrine Society, San Diego, June 14, 1999. Abstract book page 442.
92. Eastell R, **Watts N**, McClung M et al. Integrated safety analyses of risedronate in postmenopausal women. Presented at the 81st Annual Meeting of the Endocrine Society, San Diego, June 14, 1999. Abstract book page 443.
93. **Watts NB**, Eastell R, McClung M et al. Risedronate in treatment of postmenopausal osteoporosis: review of worldwide clinical efficacy results. Presented at the 81st Annual Meeting of the Endocrine Society, San Diego, June 15, 1999. Abstract book page 55.
94. **Watts N**, Roux C, Genant H et al. Risedronate reduces vertebral fracture risk after the first year of treatment in postmenopausal women with established osteoporosis. Presented at the 21st Annual Meeting of the American Society for Bone and Mineral Research, St. Louis, October 1, 1999. *J Bone Miner Res* 1999;14 (suppl 1):S136.
95. McClung M, Eastell R, **Watts N** et al. Risedronate is well-tolerated in women with postmenopausal osteoporosis. Presented at the 21st Annual Meeting of the American Society for Bone and Mineral Research, St. Louis, October 3, 1999. *J Bone Miner Res* 1999;14 (suppl 1):S538.
96. **Watts NB**, Manhart MD, Zorich NL, Pallone KA, Blank MA. Incidence of clinically upper GI perforations, ulcers, and bleeds at endoscopy is the same as placebo in patients treated with risedronate. Presented at the Annual Meeting of the American Society of Gastroenterology, Philadelphia, October 18, 1999. *Am J Gastroenterol* 1999;94:9.
97. Bone H 3rd, Adami S, Recker R et al. Alendronate 70 mg once weekly is therapeutically equivalent to alendronate 10 mg daily. Presented at the 6th Bone and Mineral Congress, Venice, Italy, November 24, 1999.
98. Bone H III, Adami S, Schnitzer T et al. Alendronate 70 mg once weekly is therapeutically equivalent to alendronate 10 mg daily. Presented at the Fifth Workshop on Bisphosphonates, Davos, Switzerland, April 5, 2000. *Bone* 2000;26 (suppl): 33S.
99. Geusens P, **Watts N**, Adami S et al. Risedronate treatment produces a rapid reduction in the risk of vertebral fractures in osteoporotic women. Presented at the Fifth Workshop on Bisphosphonates, Davos, Switzerland. April 6, 2000. *Bone* 2000;26 (suppl): 36S.
100. **Watts N**, Adachi J, Keller M et al. Risedronate is well-tolerated in postmenopausal osteoporotic women using NSAIDs or with underlying gastrointestinal disorder. Presented at the Fifth Workshop on Bisphosphonates, Davos, Switzerland, April 7, 2000. *Bone* 2000;26 (suppl): 42S.
101. **Watts NB**, Eastell R, Broy S, Adachi JD, Chines A. Risedronate treatment significantly reduces vertebral and nonvertebral fractures in osteoporotic women. Presented at the Ninth Annual Meeting and Clinical Congress of the American Association of Clinical Endocrinologists, Atlanta, May 4, 2000. Program Book page 247.
102. **Watts NB**, Roux C, Miller P, Adami S, Eastell R. Risedronate treatment significantly reduces vertebral and nonvertebral fractures in osteoporotic women. Presented at the Sixth Annual Scientific Meeting of the International Society for Clinical Densitometry, Rio de Janeiro, May 8, 2000. Program Book page 218.
103. Black DM for the Joint NOF/ISCD/ASBMR Committee on the Simplification of BMD Reporting. Revision of T-score BMD diagnostic thresholds. Presented at the World Congress on Osteoporosis 2000, Chicago, June 14, 2000. *Osteoporosis Int* 2000;11 (suppl 2):S58.

ABSTRACTS (CONTINUED):

104. Vesper HW, Demers LM, Eastell R, Ganero P, Kleerekoper M, Robins SP, Srivasta AK, Pettis JL, Warnick GR, **Watts NB**, Myers G. Guidelines on preanalytical criteria for the measurement of pyridinoline and deoxypyridinoline as bone resorption markers in urine. Presented at the World Congress on Osteoporosis 2000, Chicago, June 15, 2000. *Osteoporosis Int* 2000;11 (suppl 2):S68.
105. Lindsay R, **Watts N**, Roux C, Brown J, Barton I, Flowers K, Cooper C. Increased risk of new vertebral fracture within 1 year of an incident vertebral fracture. Presented at the World Congress on Osteoporosis 2000, Chicago, June 15, 2000. *Osteoporosis Int* 2000;11 (suppl 2):S112.
106. Adami S, Sorensen O, Eastell R, Sod E, Horlait S, **Watts N**. Risedronate rapidly reduces fracture risk in postmenopausal women with osteoporosis. Presented at the World Congress on Osteoporosis 2000, Chicago, June 17, 2000. *Osteoporosis Int* 2000;11 (suppl 2):S170.
107. **Watts N**, Bockman R, Smith C, Li Z, Eastell R, Pack S, Lindsay R. BMD change explains only a fraction of the observed fracture risk reduction in risedronate-treated patients. Presented at the World Congress on Osteoporosis 2000, Chicago, June 17, 2000. *Osteoporosis Int* 2000;11 (suppl 2):S202.
108. Eastell R, Prendergast J, Molloy M, Adachi J, Miller P, Pack S, **Watts N**. Risedronate rapidly reduces vertebral fracture risk in patients with varying degrees of osteoporotic severity. Presented at the World Congress on Osteoporosis 2000, Chicago, June 18, 2000. *Osteoporosis Int* 2000;11 (suppl 2):S208.
109. **Watts NB**, Roux C, Cooper C, Barton I, Flowers K, Lindsay R. Twenty percent of osteoporotic women taking calcium and vitamin D fracture again within 1 year of an incident vertebral fracture. Presented at the 82nd Annual Meeting of the Endocrine Society, Toronto, June 21, 2000. Program and Abstract Book page 414.
110. Harris S, Eastell R, Cohen S, Roux C, Pack S, **Watts N**. Risedronate rapidly reduces vertebral fracture risk with varying degrees of osteoporosis severity. Presented at the 82nd Annual Meeting of the Endocrine Society, Toronto, June 22, 2000. Program and Abstract Book, page 411.
111. Vesper HW, Demers LM, Eastell R, Ganero P, Kleerekoper M, Robins SP, Srivasta AK, Warnick GR, **Watts NB**. Guidelines on preanalytical criteria for the measurement of pyridinoline and deoxypyridinoline as bone resorption markers in urine. Presented at the 52nd Annual Meeting of the American Association of Clinical Chemistry, San Francisco, July 25 2000. *Clin Chem* 2000;46 (suppl 6): A37.
112. **Watts NB**. Paget's disease: diagnosis and management. Presented at the 52nd Annual Meeting of the American Association of Clinical Chemistry, San Francisco, July 27, 2000. *Clin Chem* 2000;46 (suppl 6): S37.
113. Roux C, Eriksen E, Brown J, Barton I, Passeri M, Manhart M, **Watts NB**, Lindsay R. One-in-five risk of new vertebral fracture within 1 year of an incident fracture. Presented at the 22nd Annual Meeting of the American Society for Bone and Mineral Research, Toronto, September 22, 2000. *J Bone Miner Res* 2000;15 (suppl 1):S223.
114. Delmas P, Roux C, **Watts N**, Eastell R, Pols H, Ringe J, Giraudeau B, Van de Langerijt L, Larbaoui S, Cahall D. Do bone marker results reinforce compliance and persistence to risedronate (Actonel) treatment in patients with osteoporosis? Presented at the 22nd Annual Meeting of the American Society for Bone and Mineral Research, Toronto, September 24, 2000. *J Bone Miner Res* 2000;15 (suppl 1):S429.
115. **Watts NB**, Jenkins DK, Geusens P. Comparison of bone and total alkaline phosphatase and bone mineral density in postmenopausal osteoporotic women treated with alendronate. Presented at the 22nd Annual Meeting of the American Society for Bone and Mineral Research, Toronto, September 25, 2000. *J Bone Miner Res* 2000;15 (suppl 1):S551.
116. **Watts N**, Sarkar S, Wu W, Wong M, Harper K. Validation of change in bone mineral density as a surrogate for fracture risk after statistical adjustment for imprecision in BMD measurements. Presented at the First Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society, Madrid, Spain, June 7, 2001. *Bone* 2001;28 (suppl):S93.

ABSTRACTS (CONTINUED):

117. Rizzoli R, Roux C, Greenspan S, Bone H, Schnitzer T, **Watts N**, Adami S, Foldes J, Uebelhart B, Peverly C, Santora A, Kaur A, Wu M, Orloff J. Two year results of once-weekly administration of once-weekly alendronate 70 mg for treatment of postmenopausal osteoporosis. Presented at the First Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society, Madrid, Spain, June 7, 2001. *Bone* 2001;28 (suppl):S94.
118. Greenspan S, Rizzoli R, Roux C, Bone H, Schnitzer T, **Watts N**, Adami S, Uebelhart B, Foldes J, Peverly C, Santora A, Kaur A, Orloff J. Two-year results of once-weekly administration of once-weekly alendronate 70 mg for treatment of postmenopausal osteoporosis. Presented at the 83rd Annual Meeting of the Endocrine Society, Denver, June 20, 2001. Program and Abstracts page 248.
119. **Watts NB**, Brown J, Hosking D, Adami S, Mulder H, Reginster J, Chines A, Kasibhatla C. Risedronate therapy for 5 years results in sustained reduction of vertebral fracture risk. Presented at the 83rd Annual Meeting of the Endocrine Society, Denver, June 22, 2001. Program and Abstracts page 480.
120. **Watts NB**, Brown J, Hosking D, Adami S, Mulder H, Reginster J-Y, Kasibhatla C, Chines A. Sustained fracture risk reduction over 5 years with risedronate therapy. Presented at the Annual Meeting of the American Society of Bone and Mineral Research (plenary poster), Phoenix, October 12, 2001. *J Bone Miner Res* 2001;16 (suppl 1):S212.
121. **Watts NB**, Adami S, Chesnut CH. Risedronate reduces the risk of clinical vertebral fractures in just 6 months. Presented at the Annual Meeting of the American Society of Bone and Mineral Research, Phoenix, October 14, 2001. *J Bone Miner Res* 2001;16 (suppl 1):S407.
122. Rizzoli R, Roux C, Greenspan S, Bone H, Schnitzer T, **Watts N**, Adami S, Uebelhart B, Peverly C, Kaur A, Wu M, Orloff J, Santora A. Presented at the Annual Meeting of the American Society of Bone and Mineral Research, Phoenix, October 14, 2001. *J Bone Miner Res* 2001;16 (suppl 1):S527.
123. Delmas PD, **Watts N**, Eastell R, Von Ingersleben G, van de Langerijf L, Cahall DL. Underdiagnosis of vertebral fractures is a worldwide problem. Presented at the Annual Meeting of the American Society of Bone and Mineral Research (plenary oral), Phoenix, October 15, 2001. *J Bone Miner Res* 2001;16 (suppl 1):S139.
124. Bolognese M, Chesnut C, Adami S, Barton I, **Watts N**. Risedronate reduces the risk of clinical vertebral fractures as early as 6 months and nonvertebral fractures as early as 12 months in women with postmenopausal osteoporosis. Presented at the Annual Meeting of the American College of Rheumatology, San Francisco, November 13, 2001. *Arthritis Rheum* 2001;44:S254.
125. **Watts NB**, Pols H, Ringe JD, Roux C, Horlait S, van de Langerijf L, Cahall DI, Delmas PD. Detection of "unexpected" osteoporosis: insights from the "IMPACT" trial. Presented at the Annual Meeting of the American College of Rheumatology, San Francisco, November 13, 2001. *Arthritis Rheum* 2001;44:S256.
126. **Watts NB**, Sorensen O, Eriksen E, Reginster J-Y, Chines A. Effect of 5-year risedronate therapy on fracture reduction and bone histology and histomorphometry. Presented at the Annual Meeting of the American College of Rheumatology, San Francisco, November 13, 2001. *Arthritis Rheum* 2001;44:S256.
127. Rizzoli R, Roux C, Greenspan S, Bone H, Schnitzer T, **Watts N**, Adami S, Uebelhart B, Peverly C, Kaur A, Wu M, Orloff J, Santora A for the Alendronate Once-weekly Study Group. Presented at the National Osteoporosis Fifth International Symposium: Clinical Advances in Osteoporosis, Honolulu, March 7, 2002. poster no. 94. p 25. Selected among "outstanding abstracts."
128. **Watts NB**, Li Z, Hoseyni M, Seeman E, Lindsay R. Once-a-week risedronate reduces vertebral fracture risk. Presented at the National Osteoporosis Fifth International Symposium: Clinical Advances in Osteoporosis, Honolulu, March 7, 2002. poster no. 122. p 33. Selected among "outstanding abstracts."
129. Garnero P, Eastell R, **Watts NB**, van de Langerijf L, Cahall D, Delmas PD. Short-term monitoring of risedronate therapy in postmenopausal women with markers of bone turnover: consistency in the response. Presented at the International Osteoporosis Foundation World Congress on Osteoporosis, Lisbon, May 11, 2002. *Osteoporos Int* 2002;13 (supl 1): S53.

ABSTRACTS (CONTINUED):

130. **Watts NB**, Li Z, Hoseyni MS, Seeman E, Lindsay P. Efficacy of once-a-week risedronate in reducing vertebral fracture risk. Presented at the International Osteoporosis Foundation World Congress on Osteoporosis, Lisbon, May 12, 2002. *Osteoporos Int* 2002;13 (supl 1): S17.
131. Delmas PD, Eastell R, **Watts N**, Le-Moigne-Amrani A, Grauer A, van de Langerijt L, Cahall DL. Do risk factors predict which osteoporotic women should have an x-ray to confirm prevalent vertebral fracture: the IMPACT study. Presented at the International Osteoporosis Foundation World Congress on Osteoporosis, Lisbon, May 13, 2002. *Osteoporos Int* 2002;13 (supl 1): S109.
132. **Watts NB**, Brown JP, Li Z, Lindsay R. Once-a-week risedronate reduces vertebral fracture risk. Presented at the 84th Annual Meeting of the Endocrine Society, June 22, 2002, Program and Abstracts page 575.

APPEARS THIS WAY
ON ORIGINAL

Invited Lectures at Medical Schools and Training Programs

American University of Beirut (Lebanon)	Thomas Jefferson School of Medicine
Baylor College of Medicine	University of Alabama (Birmingham)
Boston University	University of Alabama (Tuscaloosa)
Brown University	University of California, San Francisco
Cleveland Clinic	University of Cincinnati
Creighton University	University of Colorado
Duke University	University of Connecticut
Eastern Virginia School of Medicine	University of Florida (Gainesville)
Emory University	University of Florida Urban Campus (Jacksonville)
George Washington University	University of Illinois (Michael Reese Hospital)
Georgia Baptist Hospital (Atlanta Medical Center)	University of Louisville
Harvard University	University of Maryland
Henry Ford Hospital	University of Massachusetts (Worcester)
Indiana University	University of Miami
Johns Hopkins University	University of Mississippi
M.D. Anderson Cancer Center	University of North Carolina
Marshall University	University of Oklahoma
McMaster University (Canada)	University of South Alabama (Mobile)
Medical College of Georgia	University of South Carolina (Columbia)
Medical College of Virginia	University of Tennessee (Knoxville)
Medical College of Wisconsin	University of Tennessee (Memphis)
Medical University of South Carolina	University of Texas Health Science Ctr., San Antonio
Mt. Sinai Hospital, Miami	University of Toronto
New York University	University of Utah
Penn State University	University of Virginia
Pennsylvania Hospital	Vanderbilt University
Robert Wood Johnson School of Medicine	Wake Forest University
Rush-Presbyterian Hospital	Wayne State University
The Ohio State University	Yale University

Invited Lectures at National Societies

American Association of Clinical Chemists
American Association of Clinical Endocrinologists
American Association of Clinical Pathologists
American Chemical Society
American College of Clinical Endocrinologists
American College of Family Physicians
American College of Obstetricians and Gynecologists
American College of Physicians
American College of Rheumatology
American Society of Bone and Mineral Research
American Society of Gastroenterology
The Endocrine Society
International Society for Clinical Densitometry
National Osteoporosis Foundation
Public Responsibility in Medicine and Research
Southern Medical Association
World Foundation for Medical Studies in Female Health

Invited Lectures at International Meetings

Austria (Vienna)
Brazil (Recife, Rio de Janeiro)
Canada (Montreal, Quebec City, Toronto, Vancouver, Victoria)
Denmark (Aalborg, Aarhus, Copenhagen)
Egypt (Alexandria)
England (Bath, London, Oxford, Sheffield)
France (Paris, Nice)
Germany (Berlin)
Holland (Amsterdam, Maastricht)
Italy (Florence, Milan, Rome, Padua)
Japan (Osaka, Tokyo)
Lebanon (Beirut)
Portugal (Sintra)
Spain (Barcelona, Sitches)
Switzerland (Davos, Geneva)
USA (Chicago, World Congress on Osteoporosis; Honolulu, NOF Fifth International Symposium: Clinical Advances in Osteoporosis)

RECENT INVITED PRESENTATIONS

- 01/08/00 Boca Raton, Florida, Elder Floridians Association, BONES (Building Osteoporosis National Education Summit), "Treatment of Osteoporosis"
- 01/14/00 New York, New York University (NYU) Endocrinology Grand Rounds, "Glucocorticoid-induced Osteoporosis"
- 01/19/00 Washington, DC, District of Columbia Rheumatology Association and DC Bone Club, "Glucocorticoid-induced Osteoporosis"
- 01/20/00 Richmond, Medical College of Virginia, Department of Obstetrics and Gynecology Grand Rounds, "Osteoporosis;" Department of Medicine Grand Rounds, "Treatment of Osteoporosis;" Division of Endocrinology Grand Rounds, "Bisphosphonates"
- 01/22/00 Charlotte, Joint AACE/ISCD Bone Density Certification Course, "Diagnosis of Osteoporosis with Bone Densitometry," "Use of Bone Densitometry for Monitoring"
- 02/02/00 Snowmass, Clinical Diabetes and Endocrinology in 2000, "Management of Postmenopausal Osteoporosis," "Peripheral BMD Testing vs. Central DXA"
- 02/11/00 Tempe, Arizona, ISCD Conference, "Update on BMMA," "Measures to Reduce Hip Fracture Risk"
- 02/16/00 San Francisco, UCSF Division of Endocrinology Grand Rounds, "Bisphosphonate Treatment for Osteoporosis"
- 03/03/00 Gainesville, Florida, University of Florida Department of Medicine Grand Rounds, "Update on Treatments for Osteoporosis"
- 03/04/00 Gainesville, Florida, University of Florida Department of Obstetrics and Gynecology Grand Rounds, "Emerging Trends in Osteoporosis"
- 03/09/00 Philadelphia, Thomas Jefferson University Department of Medicine Grand Rounds, "Bisphosphonates"
- 03/09/00 Philadelphia, Thomas Jefferson University Division of Rheumatology, "Paget's Disease"
- 03/11/00 New Orleans, American College of Rheumatology Spring Meeting, "When is Osteoporosis not Osteoporosis?"
- 03/24/00 Geneva, University of Sheffield and Roche Pharmaceuticals, Workshop on Bone Markers: Biochemical and Clinical Perspectives, panel member
- 04/12/00 Alexandria, Egypt, Third Egyptian Congress on Endocrinology and Obesity, "Secondary Causes of Osteoporosis"
- 04/13/00 Alexandria, Egypt, Third Egyptian Congress on Endocrinology and Obesity, "Management of Postmenopausal Osteoporosis"
- 04/27/00 Houston, Baylor College of Medicine and University of Texas at Houston Endocrinology Grand Rounds, "Glucocorticoid-Induced Osteoporosis"
- 05/03/00 Atlanta, Ninth Annual Meeting, American Association of Clinical Endocrinologists Satellite Symposium, "Recent Clinical Data on New Anti-resorptive Agents for the Treatment of Osteoporosis"
- 05/03/00 Atlanta, Ninth Annual Meeting, American Association of Clinical Endocrinologists Satellite Symposium, "Role of Anti-resorptive Agents in the Treatment of Osteoporosis: A Review of the Prospective Clinical Trials"
- 05/07/00 Atlanta, Ninth Annual Meeting, American Association of Clinical Endocrinologists, Plenary Lecture, "Bisphosphonates and Osteoporosis"
- 05/10/00 Rio de Janeiro, Sixth Annual Scientific Meeting, International Society for Clinical Densitometry, Plenary Lecture, "Densitometric Diagnosis of Osteoporosis"
- 05/16/00 District of Columbia Endocrinology Club, "Treatment of Osteoporosis"
- 06/06/00 Salt Lake City, University of Utah Department of Obstetrics and Gynecology Grand Rounds, "Postmenopausal Osteoporosis"
- 06/07/00 Baltimore, Johns Hopkins Hospital Division of Endocrinology Grand Rounds, "Bisphosphonates: History, Mechanisms of Action, Clinical Uses"
- 06/16/00 Chicago, World Congress on Osteoporosis, "Estrogen in the Early Postmenopause"
- 06/29/00 Norfolk, Eastern Virginia School of Medicine Department of Obstetrics and Gynecology Grand Rounds, "Postmenopausal Osteoporosis"
- 07/27/00 San Francisco, American Association of Clinical Chemists Annual Meeting, "Paget's Disease"
- 09/05/00 Detroit, Henry Ford Hospital, Endocrinology Grand Rounds, "Biochemical Markers of Bone Remodeling"
- 09/06/00 Detroit, Wayne State University, Department of Medicine Grand Rounds, "Postmenopausal Osteoporosis"
- 09/06/00 Detroit, Wayne State University, Division of Endocrinology Grand Rounds, "Bisphosphonates"

RECENT INVITED PRESENTATIONS (CONTINUED):

- 09/08/00 Tuscaloosa, University of Alabama, Family Medicine Grand Rounds, "Postmenopausal Osteoporosis"
- 09/15/00 Cleveland, The Cleveland Clinic, Combined Endocrinology and Rheumatology Grand Rounds, "Glucocorticoid-induced Osteoporosis"
- 09/23/00 Toronto, American Society of Bone and Mineral Research Annual Meeting, "Combination Therapy for Osteoporosis"
- 10/04/00 Beirut, American University of Beirut, Department of Medicine Grand Rounds, "Postmenopausal Osteoporosis"
- 10/05/00 Beirut, International Osteoporosis Foundation Pan-Arab Osteoporosis Congress, "Bone Quality and Fractures"
- 10/11/00 Providence, Rhode Island, Brown University School of Medicine, Endocrinology Grand Rounds, "Bisphosphonates"
- 10/12/00 Farmington, University of Connecticut School of Medicine, Endocrinology Grand Rounds, "Bisphosphonates"
- 10/12/00 York Harbor, Maine, New England Bone Club, "How do Osteoporosis Treatments Reduce the Risk of Fracture?"
- 10/13/00 Boston, Beth Israel Deaconess Hospital Endocrinology Grand Rounds, "How do Osteoporosis Treatments Reduce the Risk of Fracture?"
- 12/15/00 Omaha, Creighton University, Endocrinology Grand Rounds, "Bisphosphonates"
- 02/16/01 Indianapolis, Indiana University Endocrinology and Bone Conference, "Does Fracture Risk Reduction Correlate with Change in BMD with Osteoporosis Treatment?"
- 03/08/01 San Antonio, University of Texas Health Sciences Center Division of Endocrinology Grand Rounds, "Does Fracture Risk Reduction Correlate with Change in BMD with Osteoporosis Treatment?"
- 04/07/01 Athens, Greece, Osteoporosis Symposium, "Special Issues with Osteoporosis in the Elderly"
- 04/28/01 Atlanta, Satellite Meeting of American Association of Endocrine Surgeons, "Management of Hyperthyroidism," "Issues with Hyperparathyroidism"
- 05/03/01 San Antonio, American Association of Clinical Endocrinologists Annual Meeting, "Osteoporosis" workshop with Michael McClung MD
- 05/12/01 Niagara Falls Ontario, Osteoporosis in Canada Symposium, "Bisphosphonates: Mechanism of Action, Role in Osteoporosis Therapy"
- 06/05/01 Madrid, ISCD/IOF Symposium at IBMD-ECTS Joint meeting, "Monitoring Patients on Antiresorptive Therapy for Osteoporosis."
- 06/20/01 Denver, Annual Meeting of The Endocrine Society, Lilly Satellite Symposium on Osteoporosis, "Current Role of Antiresorptive Therapy"
- 06/22/01 Denver, Annual Meeting of The Endocrine Society, Procter & Gamble Satellite Symposium on Osteoporosis, "Vertebral Fractures in Osteoporosis: New Insights"
- 06/23/01 Denver, Annual Meeting of The Endocrine Society, Meet the Professor, "Metabolic Bone Diseases"
- 07/01/01 Vancouver, Western Osteoporosis Alliance "Management of Osteoporosis in the Elderly"
- 10/26/01 Columbus, Ohio, Ohio Medical Education Network (OMEN), "Management of Glucocorticoid-induced Osteoporosis"
- 10/30/01 Memphis, TN, University of Tennessee, Endocrinology Grand Rounds, "Bisphosphonates and Osteoporosis"
- 11/02/01 Novi, MI, Michigan Consortium for Osteoporosis, Emerging Issues in Osteoporosis, "Quality Assurance Standards in Osteoporosis"
- 11/08/01 Nashville, TN, Vanderbilt University Endocrinology Conference, "New Concepts in Osteoporosis"
- 11/09/01 Nashville, TN, Southern Medical Association, "Treatment of Osteoporosis"
- 11/13/01 San Francisco, Annual Meeting of the American College of Rheumatology, Procter & Gamble Satellite Symposium, "New Insights in the Treatment of Osteoporosis"
- 12/03/01 Boston, Annual Meeting of Public Responsibility in Medicine and Research (PRIM&R); debate (with Richard O'Brien), "Is it Ethical to Use Placebos in Osteoporosis Trials?"
- 12/08/01 Prague, Czech Republic, International Osteoporosis Foundation / International Society for Clinical Densitometry program for Central and Eastern Europe, program organizer and speaker.
- 12/18/01 New York, World Foundation for Medical Studies in Female Health, "Osteoporosis: Who to Test, Who to Treat?"

RECENT INVITED PRESENTATIONS (CONTINUED):

- 02/15/02 Atlanta, International Society of Clinical Densitometry Annual Meeting Keynote Address, "Osteoporosis: Who to Test, Who to Treat"
- 02/16/02 Atlanta, International Society of Clinical Densitometry Annual Meeting (debate with John Kanis), "T Scores Should Be Retained for Diagnosis of Osteoporosis"
- 03/08/02 Honolulu, National Osteoporosis Foundation World Congress, "Treatments Should be Monitored with BMD" (debate with Steven Cummings MD)
- 03/08/02 Honolulu, National Osteoporosis Foundation World Congress, Meet the Professor, "Clinical Uses of Bone Densitometry"
- 03/15/02 Houston, MD Anderson Cancer Center Institutional Grand Rounds, "Bisphosphonates for Osteoporosis"
- 03/20/02 Davos, Switzerland, Sixth Workshop on Bisphosphonates, "Bisphosphonates and Osteoporosis"
- 04/18/02 Louisville, Kentucky, University of Louisville Department of Medicine Grand Rounds, "Osteoporosis: Who to Test, Who to Treat"
- 05/18/02 Rehoboth Beach, DE, American College of Physicians Delaware Chapter, "Postmenopausal Osteoporosis"
- 06/11/02 Bethesda, Cystic Fibrosis Foundation Consensus Conference on Bone Health and Bone Disease in Cystic Fibrosis, "Bone Densitometry: Science and Technology"
- 06/19/02 San Francisco, 84th Annual Meeting of the Endocrine Society, Meet the Professor, "Bone Densitometry"
- 06/20/02 San Francisco, 84th Annual Meeting of the Endocrine Society, Plenary Presentation, "Clinical Densitometry in the Evaluation of Metabolic Bone Diseases"
- 06/22/02 San Francisco, 84th Annual Meeting of the Endocrine Society, Meet the Professor, "Bone Densitometry"
- 07/16/02 Winston-Salem NC, Wake Forest University Division of Rheumatology weekly conference, "Glucocorticoid-induced Osteoporosis"
- 07/30/02 Orlando, Annual Meeting of the American Association of Clinical Chemistry, "Guidelines and Algorithms, Past and Future: What Works, What Doesn't, and Why"
- 08/16/02 Cleveland Clinic, Endocrinology Grand Rounds, "Hormone Replacement Therapy: Pendulum Swing or Paradigm Shift"
- 08/27/02 Huntington, West Virginia, Marshall University School of Medicine, Internal Medicine Grand Rounds, "Hormone Replacement Therapy: Pendulum Swing or Paradigm Shift"
- 09/14/02 Toronto, Canada, University of Toronto, City-Wide Osteoporosis Conference, "Vertebroplasty, Kyphoplasty, and other Modalities for Managing Vertebral Fractures"
- 09/21/02 San Antonio, American Society for Bone and Mineral Research Annual Meeting, State of the Art plenary presentation, "Ethics of Placebos in Osteoporosis Trials"
- 09/29/02 Charlottesville, Virginia Society of Rheumatologists Annual Meeting, "Treatment of Postmenopausal Osteoporosis"